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Summary 
Introduction 
Health Problem 
Coronary artery disease (CAD), which is a manifestation of atherosclerosis of 
the coronary arteries, belongs to the most prevalent diseases and it is the lead-
ing cause of death in Austria. Apart from an increased mortality risk, CAD 
is associated with recurring discomfort, impaired quality of life, and repeat-
ed hospitalisation. 
 
Description of Technology 
Different revascularisation techniques have been developed to restore blood 
flow. The most common approach today is percutaneous coronary interven-
tion (PCI), which widens stenotic coronary arteries. PCI includes angioplas-
ty and the implantation of a coronary stent or scaffold that holds a blocked 
vessel open.  
The earliest types of stents were bare metal stents (BMS). Later, drug eluting 
stents (DES) were developed. The most recent developments in stent tech-
nology are fully bioresorbable vascular scaffolds (BVS), designed to slowly 
disappear over time. To date, two products (ABSORB®, DESolve®) have re-
ceived CE-mark. This review evaluates whether the implantation of a BVS in 
patients with CAD has a better benefit-harm profile than other revasculari-
sation approaches.  
 
Methods 
The analysis is based on a systematic literature search, complemented by a 
hand search and manufacturer requests. The studies were systematically as-
sessed for quality and risk of bias. Data on each selected outcome category 
were synthesised across studies according to the “Grading of Recommenda-
tions Assessment, Development and Evaluation” (GRADE).  
 
Results 
Available evidence 
For evaluating the efficacy of the BVS (ABSORB®), nine- and 12-months in-
terim results from two randomised controlled trials (RCT) with 741 partic-
ipants were available, comparing the BVS with three types of drug-eluting 
stents. No evidence was available for evaluating the efficacy of the BVS 
DESolve®. 
For evaluating the safety of the BVS ABSORB®, in addition to the RCTs, ten 
observational studies (mostly single-arm) fulfilled our inclusion criteria. Over-
all, safety data from 1,290 patients who received a BVS and from 486 pa-
tients with traditional stents were available. For evaluating the safety of the 
DESolve®, one single-arm observational study (16 patients) was available. 
 
coronary artery disease 
(CAD) causes major 
burden of disease 
PCI most common 
revascularisation 
technology 
different stent types 
 
latest development: 
bioresorbable scaffolds 
systematic literature 
search, data synthesis 
with GRADE 
efficacy only for 
ABSORB®: 2 RCTs 
safety ABSORB®: 2 RCTs 
+ 10 observational 
studies 
 
DESolve: one small  
case series 
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Clinical effectiveness 
After 12 months, (cardiac) mortality, myocardial infarction, revascularisation 
and quality of life did not significantly differ between patients who received 
a BVS compared to those who received a DES. An equal proportion in both 
groups was free from angina. The cumulative angina rate was lower in the 
BVS than in the DES group; however, this is based on a post-hoc analysis. 
 
Safety 
Short-term data with moderate strength of evidence showed scaffold throm-
bosis in <1.5 % of BVS-patients and no stent thrombosis in the control 
groups. Less than 1 % of participants died from either periprocedural mor-
tality or from cardiovascular mortality in the intervention and control groups 
respectively.  
 
Upcoming evidence 
At least 14 RCTs and 20 single-arm studies are currently registered. They 
include around 32,120 patients in total and will potentially influence the es-
timate of effect considerably. 
 
Reimbursement 
PCI and stenting are hospital based procedures and are therefore reimbursed 
via the Austrian DRG-system (Leistungsorientierte Krankenanstaltenfinan-
zierung/LKF). The BVS has not received a separate reimbursement code so 
far. The price per device is currently € 825. 
 
Discussion 
The quality of evidence is limited because of study design issues (lack of com-
parison group, no blinding of outcome assessors or patients, short time-hori-
zon). The results primarily apply to male patients with stable CAD and rela-
tively simple lesions which do not necessarily represent routine CAD pa-
tients. Late scaffold thrombosis and its adverse consequences, which are very 
relevant safety outcomes, require longer follow-up times. 
 
Conclusion 
The current evidence is not sufficient to prove that the BVS is more or at 
least equally effective and safer than current revascularisation technologies. 
Hence, the inclusion in the catalogue of benefits is currently not recommend-
ed. We suggest re-evaluation in 2018. 
  
no difference in 
cardiovascular 
morbidity, mortality and 
revascularisation 
short-term safety:  
very few serious  
adverse events 
studies with 32,000 
patients ongoing 
reimbursement via 
PCI/stent flat rate 
limitation of evidence 
due to study design, 
limited applicability in 
routine and short 
follow-up 
inclusion in benefit 
catalogue currently  
not recommended 
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Zusammenfassung 
Einleitung 
Hintergrund 
Die koronare Herzkrankheit (KHK) ist eine Manifestation von Atherosklero-
se der Herzarterien. Die KHK gehört zu den häufigsten Krankheiten in in-
dustrialisierten Ländern und führt in Österreich die Todesursachenstatistik 
an. Neben dem erhöhten Sterblichkeitsrisiko ist die KHK mit erheblichen 
Einschränkungen (reduzierte körperliche Belastbarkeit, Schmerzen, Depres-
sion etc.) und mit wiederholten Spitalsaufenthalten für die PatientInnen ver-
bunden. 
 
Beschreibung der Technologie 
Es wurden mehrere Verfahren entwickelt, um die verengten Blutgefäße offen-
zuhalten oder operativ mittels eines Bypasses zu überbrücken. Am häufigs-
ten kommt derzeit die perkutane koronare Intervention (PCI) zum Einsatz, 
bei der das verengte Gefäß mit einem Ballon geweitet und ein Röhrchen aus 
Drahtgeflecht – ein sogenannter Stent – eingesetzt wird.  
Die ersten Stents waren unbeschichtete Metallstents. Da es durch die physio-
logische Antwort auf die durch das Implantat entstehende Gefäßverletzung oft 
zu erneuten Stenosen kam, wurden medikamentenfreisetzende Stents (DES) 
entwickelt, die durch eine antiproliferative und/oder immunsuppressive Wir-
kung die Restenose verhindern sollten. Allerdings stellten bei der ersten DES-
Generation späte Stentthrombosen ein Sicherheitsrisiko dar.  
Die neueste Entwicklung sind vollständig resorbierbare Gefäßgerüste (BVS), 
die nach einiger Zeit gänzlich abgebaut werden. Derzeit sind zwei Produkte 
(ABSORB®, DESolve®) in Europa zugelassen. Sie bestehen aus einem resor-
bierbaren Polymer Poly (L-Lactid) (PLLA) Gerüst, das mit einem medika-
mentenfreisetzenden Polymer beschichtet ist. Die amerikanische Zulassungs-
behörde hat bisher noch kein Produkt zugelassen. Zahlreiche weitere resor-
bierbare Gefäßgerüste werden derzeit in klinischen Studien getestet.  
 
Indikation und therapeutisches Ziel 
Die BVS wurden mit der Intention entwickelt, die Vorteile der unbeschich-
teten Metallstents und der DES zu kombinieren. Insbesondere soll das späte 
Thromboserisiko durch die Verhinderung eines permanenten Implantats re-
duziert werden. Möglicherweise kann die begleitende Therapie mit Gerin-
nungshemmern verkürzt werden, und in Stent-freien Blutgefäßen ist eine 
spätere invasive Therapie (Bypass) leichter durchführbar. 
Die Implantate sind für PatientInnen mit KHK, welche für eine PCI in Frage 
kommen, indiziert, allerdings dürfen die Gefäße keine hochgradigen Verkal-
kungen aufweisen. Ein österreichisches Spital empfiehlt, vorrangig Diabeti-
kerInnen unter 75 Jahren zu behandeln. 
 
 
koronare Herzkrankheit 
(KHK) führt 
Todesursachenstatistik 
an 
PCI oder Bypass als 
Revaskularisierung 
mit früheren Stents 
Restenose- und 
Stentthromboserisiko 
neu:  
2 zugelassene 
resorbierbare 
Gefäßgerüste (BVS) 
BVS soll Vorteile von 
bisherigen Stents 
kombinieren 
indiziert bei KHK,  
falls PCI sinnvoll, jedoch 
Gefäße ohne Verkalkung 
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Methode 
Sowohl die Analyse der Wirksamkeit, als auch der Sicherheit basiert auf ei-
ner systematischen Literatursuche in medizinischen Datenbanken, die mit 
einer Handsuche, sowie Anfragen an die Hersteller ergänzt wurde. Relevante 
Studien wurden nach vorher definierten Ein- und Ausschlusskriterien aus-
gewählt und auf Qualität und Verzerrungsrisiko überprüft.  
Als relevante Outcomes für die Beurteilung der Wirksamkeit wurden die (kar-
diovaskuläre) Mortalität und Morbidität (Herzinfarkt, Angina Pectoris), die 
Lebensqualität und die Revaskularisierungsraten definiert. Für die Beurtei-
lung der Sicherheit wurden die Indikatoren „Stentthrombose inkl. schwer-
wiegender Konsequenzen“, „periprozedurale Mortalität oder Mortalität durch 
Blutung/Schlaganfall“ und „sonstige schweriegende unerwünschte Ereignisse 
(z.B. Schlaganfall) als entscheidend definiert.  
Daten zu den als relevant definierten Outcomes wurden mit der Methode 
„Grading of Recommendations Assessment, Development and Evaluation“ 
(GRADE) zusammenfassend analysiert. 
 
Ergebnisse 
Verfügbare Evidenz 
Die Beurteilung der Wirksamkeit ist lediglich für das Gefäßgerüst ABSORB® 
möglich. Hierfür standen neun- und 12-Monats Interimsergebnisse zweier ran-
domisiert kontrollierter Studien (RCT) mit insgesamt 741 (primär männli-
chen) PatientInnen zur Verfügung. In den Studien wurde der BVS mit drei 
Typen von medikamentenfreisetzenden Stents verglichen. Der Großteil der 
PatientInnen litt an stabiler CAD, ein kleiner Anteil hatte ein akutes Koro-
narsyndrom.  
Für die Beurteilung der Sicherheit des BVS ABSORB® standen – zusätzlich 
zu den RCTs – zehn Beobachtungsstudien zur Verfügung. Davon waren acht 
einarmig und zwei kontrolliert. In acht Beobachtungsstudien litten die Pati-
entInnen unter stabiler KHK, in zwei unter akutem Koronarsyndrom. In Sum-
me standen für die Beurteilung der Sicherheit Daten von 1.290 PatientIn-
nen, die mit dem BVS behandelt wurden und von 486 PatientInnen, die mit 
herkömmlichen Stents (primär DES) behandelt wurden, zur Verfügung. 
Für die Beurteilung der Sicherheit des BVS DESolve® stand eine einarmige 
Beobachtungsstudie mit 16 PatientInnen mit stabiler KHK zur Verfügung. 
Diese untersuchte jedoch einen Myolimus-freisetzenden Prototyp, während 
das am Markt befindliche Produkt Novolimus freisetzt.  
 
Klinische Wirksamkeit 
Nach 12 Monaten waren bei PatientInnen, die das resorbierbare Gefäßgerüst 
erhielten, die (kardiale) Sterblichkeit, der Anteil der Herzinfarkte und die 
Häufigkeit von neuerlichen Vaskularisierungsmaßnahmen nicht signifikant 
geringer als bei jenen, die einen herkömmlichen Stent erhielten. Auch die 
Lebensqualität wurde nicht höher bewertet. Ein gleicher Anteil von Patien-
tInnen in beiden Gruppen war ohne Angina Pectoris Anzeichen. Die kumu-
lative Angina Rate war in der BVS-Gruppe niedriger, allerdings basiert die-
ses Ergebnis auf einer post-hoc Analyse. 
 
systematische 
Literaturrecherche 
relevante Outcomes für 
Wirksamkeit und 
Sicherheit 
Synthese mit GRADE 
Wirksamkeitsdaten nur 
für ABSORB®: 2 RCTs 
mit 750 PatientInnen 
Sicherheit ABSORB®:  
10 Beobachtungsstudien 
+ 2 RCTs mit  
1.800 PatientInnen, 
primär stabile KHK 
DESolve®: 1 Fallserie,  
16 PatientInnen 
kein Unterschied bei 
Morbidität, Sterblichkeit 
und Revaskularisierung 
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Sicherheit 
Bei Beobachtung bis zu zwölf Monaten traten in Summe neun BVS-bedingte 
(<1,5 % der PatientInnen) und keine Stent-bedingten Thrombosen auf. We-
niger als 1 % der StudienteilnehmerInnen in beiden Gruppen starben bei der 
Intervention oder aufgrund späterer kardio-vaskulärer Ursachen.  
 
Laufende Studien 
Derzeit sind zumindest 14 laufende RCTs und 30 einarmige Studien regis-
triert. In diesen Studien sollen in Summe 32.120 PatientInnen teilnehmen. 
Dadurch kann sich die derzeitige Einschätzung zur Wirksamkeit und Sicher-
heit noch deutlich verändern.  
 
Kostenerstattung 
PCI und Stents werden über ein spezifisches Fallpauschale im Rahmen der 
Leistungsorientierten Krankenanstaltenfinanzierung erstattet. Das vollstän-
dig resorbierbare Gefäßgerüst hat derzeit keinen separaten Code und wird 
daher im Rahmen des PCI/Stent Pauschale refundiert. Der Preis pro BVS 
liegt laut Auskunft der Hersteller derzeit für das BVS ABSORB® bei 825 €. 
 
Diskussion 
Nach den derzeitigen Schlüsselstudien ist die Implantation eines vollständig 
resorbierbaren Gefäßgerüstes hinsichtlich patientInnenrelevanter Endpunkte 
nicht wirksamer als herkömmliche Stents. Es konnte bisher auch kein besse-
res Sicherheitsprofil ausgewiesen werden. Allerdings erfolgten die Nachbe-
obachtungen in den vergleichenden Studien maximal bis 12 Monate, sodass 
über die Häufigkeit von sehr späten Stentthrombosen noch keine Aussage 
möglich ist. Außerdem treten Stentthrombosen, wie auch andere schwerwie-
gende unerwünschte Ereignisse vergleichsweise selten auf, ein signifikanter 
Gruppenunterschied ist daher generell schwer nachweisbar. Die große An-
zahl laufender Studien mit über 30.000 PatientInnen wird jeoch eine siche-
rere Aussage über das Nutzen-Schadensprofil ermöglichen.  
Limitierend für die Aussagekraft der derzeitigen Daten ist das Studiendesign. 
Es waren teilweise die befundenden Personen und/oder die PatientInnen nicht 
verblindet. Im Großteil der Beobachtungsstudien gab es keine Kontrollgrup-
pe und die Auswahl der PatientInnen oblag den behandelnden ÄrztInnen. 
Dadurch könnten genau jene PatientInnen mit dem BVS behandelt worden 
sein, die die beste Prognose haben. 
Da in den Studien vorwiegend einfache Läsionen bei PatientInnen mit stabi-
ler KHK behandelt wurden, und die TeilnehmerInnen überwiegend männ-
lich waren, sind die Ergebnisse auf klassische RoutinepatientInnen mit kom-
plexeren Läsionen oder mit akuter Erkrankung und auf Frauen nur sehr ein-
geschränkt übertragbar.  
 
  
kurzfristig kaum 
schwere Komplikationen 
32.000 PatientInnen  
in 14 RCTs und  
30 Beobachtungsstudien 
untersucht 
Bezahlung über 
PCI/Stent-Pauschale 
 
Preis pro Stück: 825 € 
derzeit (noch) kein 
Beleg für überlegenes 
Nutzen-Schadensprofil 
des BVS  
 
Nachbeobachtung für 
späte Thrombosen zu 
kurz 
 
laufende Studien 
bringen mehr 
Gewissheit 
 
 
Limitationen durch 
Studiendesign 
keine Daten für akute 
KHK und komplexe 
Läsionen 
Fully bioresorbable scaffolds for coronary artery disease 
12 LBI-HTA | 2015 
Empfehlung  
Die derzeitige Evidenz ist nicht ausreichend um zu belegen, dass der BVS 
wirksamer und sicherer oder zumindest gleich wirksam aber sicher als die 
herkömmlichen Revaskulaisierungstechnologien sind. Daher wird eine Auf-
nahme in den Krankenhaus-Leistungskatalog derzeit nicht empfohlen. Auf-
grund der zahlreichen laufenden Studien empfehlen wir eine neuerliche Eva-
luierung im Jahr 2018. 
 
Aufnahme in 
Leistungskatalog derzeit 
nicht empfohlen 
 
Re-Evaluierung 2018 
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1 Scope 
1.1 Research questions 
This report addresses the following research question: Is the implantation of 
a fully bioresorbable scaffold (BVS), in comparison to other revascularisation 
strategies (permanent stent, coronary artery bypass grafting/CABG) in adult 
patients with coronary artery disease (CAD) more effective and safe or equally 
effective but safer concerning cardiovascular mortality, morbidity and health-
related quality of life? 
 
 
1.2 Inclusion criteria 
Inclusion criteria for relevant studies are summarised in Table 1.2-1. 
Table 1.2-1: Inclusion criteria 
Population Adult patients with CAD including stable angina, unstable angina, myocardial 
infarction (ICD-10 code I20-I25) who require and are eligible for myocardial 
revascularisation  
MeSH-terms: Heart Disease [C14.280], Myocardial Ischemia [C14.280.647],  
Acute Coronary Syndrome [C14.280.674.124] Angina Pectoris [C14.280.647.124], 
Coronary Disease [C14.280.647.250], Coronary Artery Disease [C14.280.64], 
Myocardial Infarction [C14.280.674.7.250.260]  
Intervention Percutaneous coronary intervention (PCI) with implantation of a fully 
bioabsorbable/biodegradable/bioresorbable vascular scaffold/stent (BVS) 
Product names: Absorb, DESolve, DREAMS, IDEAL, Igaki-Tamai, Fantom, ART18Z 
Trials: ABSORB, BIOSOLVE, DESolve Nx-Trial, ARTDIVA, RESTORE 
MeSH terms: Percutaneous Coronary Intervention [E04.100.814.529.968],  
Stents [E07.695.750], Drug-Eluting Stents [E07.695.750.500] 
Control PCI with implantation of other stent types or other revascularisation strategies 
MeSH-terms: Percutaneous Coronary Intervention [E04.100.814.529.968],  
Stents [E07.695.750], Drug-Eluting Stents [E07.695.750.500],  
Coronary Artery Bypass [E04.100.376.719.332] 
Rationale: PCI with implanting a permanent drug eluting or bare metal stents or with 
a bioresorbable polymer drug eluting stent is currently the main strategy to treat CAD; 
another alternative for revascularisation is coronary artery bypass grafting (CABG), 
which may result in more complete revascularisation, yet with a higher procedural risk. 
Outcomes  
Efficacy Clinical endpoints:  Mortality (cardiac, all-cause)  
  Morbidity: angina, myocardial infarction 
  Quality of life 
Composite endpoints: Major adverse cardiac events (MACE)  
Surrogate endpoints: Re-vascularisation: target vessel revascularisation (TVR), 
target lesion revascularisation (TLR) 
Rationale: CAD is associated with an increased risk of mortality and with impaired 
quality of life, reduced physical endurance, mental depression and recurrent 
hospitalisation or outpatient visits. Revascularisation should, therefore, ideally 
prolong life-expectancy, reduce the symptoms and future revascularisations, and 
increase health-related quality of life. 
PIKO-Frage 
Einschlusskriterien 
Fully bioresorbable scaffolds for coronary artery disease 
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Safety Adverse events 
 vascular access-site complication 
 procedure-related contrast-induced nephropathy 
Serious adverse events 
 late/very late scaffold/stent thrombosis and its consequences  
 bleeding from anti-platelet therapy  
 periprocedural myocardial infarction or mortality 
 mortality from bleeding/stroke 
 other serious adverse events  
Rationale: Compared to CABG, PCI + stenting has lower periprocedural risks but 
bears the risk of late stent thrombosis with potentially severe consequences. 
Furthermore, the treatment requires long-term anti-platelet therapy which bears the 
risk of potentially life-threatening bleeding. Finally, PCI + stenting can be associated 
with complications at the vascular access site or with nephropathy due to contrast 
media used in the coronary angiography. 
Study design  
Efficacy  Randomised controlled trials (follow-up ≥6 months)  
Safety Randomised controlled trials (follow-up ≥6 months) 
Prospective non-randomised controlled trials (follow-up ≥6 months) 
Prospective (single-arm) observational studies, e.g. case series, registries,  
(≥15 patients; follow-up ≥1 month)1 
 
 
1.3 Literature search 
The systematic literature search was conducted on the 6th of January 2015 in 
the following databases:  
 Medline via Ovid  
 Embase  
 The Cochrane Library  
 CRD (DARE – NHS EED – HTA)  
Search filters were applied in Medline and Embase to limit the systematic 
search to clinical trials and systematic reviews. After deduplication, 906 cita-
tions overall were included for abstract screening. The specific search strate-
gy employed can be found in the Appendix (“Literature search”).  
Manufacturers from the two products with CE-marks (ABSORB®, DESolve®) 
submitted 12 publications, of which four new citations were identified.  
An additional 55 citations were found by handsearch, one additional RCT 
was published after the literature search and was also added, resulting in 966 
hits in total. 
 
 
                                                             
1 Short-term follow-up studies were included to obtain data for immediate/peripro-
cedural complications.  
systematische 
Literaturrecherche in 
Datenbanken und Web 
Literatursuche: 
906 Ergebnisse 
Hersteller:  
4 Publikationen  
mit Handsuche  
gesamt 966 Zitate  
Scope 
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1.4 Flow chart study of selection 
Overall 966 hits were identified. The references were screened by two inde-
pendent researchers and in case of disagreement a third researcher was in-
volved to solve the differences. The selection process is displayed in Figure 
1.4-1. 
 
Figure 1.4-1: Flow chart of study selection (PRISMA Flow Diagram) 
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2 Description and technical 
characteristics of technology 
2.1 Methods 
Research questions 
Element ID Research question 
Importance 
2 = critical 
1 = optional 
B0001  What is the BVS and what are other revascularisation technologies? 2 
A0020  For which indications has the BVS received marketing authorisation or 
CE marking? 
2 
B0002  What is the claimed benefit of the BVS in relation to other 
revascularisation techniques? 
2 
B0003  What is the phase of development and implementation of the BVS and 
of other revascularisation technologies? 
2 
B0004  Who administers the use of revascularisation technologies in CAD and 
in what context and level of care are they provided? 
2 
B0008  What kind of special premises are needed to use revascularisation 
technologies in CAD? 
1 
B0009  Which supplies are needed to use revascularisation technologies in CAD? 1 
A0021  What is the reimbursement status of the BVS? 1 
 
Sources 
The information provided in this chapter is based on different sources: firstly, 
relevant references identified in the systematic database search (see Chapter 
1.3) were used [1-4], supplemented by hand search for clinical guidelines [5-
9] and by information provided by clinical experts and by manufacturers on 
request.  
 
 
2.2 Results 
Features of the technology and comparators 
B0001 – What is the BVS and what are other revascularisation 
technologies? 
Revascularisation techniques started in the 1960s with the advent of bypass 
surgery. In the 1970s, the first percutaneous coronary interventions (PCI), 
which widen stenotic coronary arteries, were performed. They have become 
one of the most common interventions in the treatment of CAD. PCI includes 
percutaneous transluminal balloon angioplasty and the implantation of cor-
onary vascular stents or scaffolds that hold a blocked vessel open [2, 7].  
Quellen: systematische 
Datenbanksuche, 
Handsuche, Hersteller 
PCI ist gängige 
Revaskularisierung 
Fully bioresorbable scaffolds for coronary artery disease 
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The earliest types of stents were bare metal stents (BMS). Later, drug eluting 
stents (DES) were developed and have been widely used since then. In the 
second generation of DES, bioresorbable drug eluting polymers have been 
used, which, however, leave behind a residual metal platform after six to nine 
months. The most recent developments in stent technology are fully biore-
sorbable vascular scaffolds designed to slowly disappear over time. They are 
composed of either a polymer or metallic alloy. Some of them are drug-coated, 
while others are not [3] (Table 2.2-1). 
This report will evaluate the efficacy and safety of implanting a fully biore-
sorbable vascular scaffold (sometimes also called bioabsorbable or biode-
gradable stent/scaffolds) in comparison with other revascularisation tech-
niques: implanting other (permanent) stent types (permanent bare metal or 
drug eluting stent, bioresorbable polymer drug eluting stent) and coronary 
artery bypass grafting (CABG).  
 
A0020 – For which indications has the BVS received marketing 
authorisation or CE marking?? 
To date two products (ABSORB®, DESolve®) have received CE-marking for 
implanting the devices in adult patients with CAD (see Table 2.2-1). None 
of the products has been approved by the US market authorisation agency 
(FDA) so far.  
The ABSORB® scaffold (Abbott Vascular) received CE-marking in 2010. It 
consists of a resorbable polymer poly (L-lactide) (PLLA) scaffold that is 
coated with an everolimus eluting resorbable poly (D, L-lactide) (PDLLA) 
polymer. It dissolves completely within several years.  
The DESolve® scaffold (Elixir Medical) received CE-marking in 2014. It al-
so consists of a polymer poly (L-lactide) (PLLA) scaffold. Coating consists of 
a Poly-Lactid-based polymer which elutes novolimus.  
Several further fully bioabsorbable scaffolds are currently being developed 
and tested (see Table 2.2-1). This report will cover the CE-marked devices 
only. 
inkludiert Stenting mit 
unterschiedlichen 
Stenttypen 
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Gefäßgerüste (BVS) 
Bericht untersucht BVS 
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2 Produkte mit  
CE-Mark: 
ABSORB® 
DESolve® 
weitere in Entwicklung 
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Table 2.2-1: Overview of fully bioresorbable scaffolds 
Company Device Name Drug 
CE-
Certificate 
FDA 
Approval Comment 
Polymeric 
Abbott Vascular 
(IL) 
ABSORB® Everolimus Yes (2010) No ABSORB II trial + further trials 
Elixir Medical 
(CA) 
DESolve® Novolimus Yes (2014) No DESolve Nx Trial 
Bioabsorbable 
Therapeutics Inc. 
(CA) 
IDEAL  Sirolimus No No  
Reva Medical Inc. 
(CA) 
FantomTM Sirolimus No 
(expected 
in 2016) 
No RESTORE trial; First human 
implants initiated in Dec 2014, 
first generation product: ReZolve 
Amaranth 
Medical 
FORTUTUDE Sirolimus No No Mend-II trial 
Kyoto Medical 
Planning (Japan) 
Igaki-Tamai® None No No Igaki-Tamai® stent for peripheral 
artery received the CE mark 
Arterial 
Remodelling 
Technologies 
(France) 
ART18Z None No No ARTDIVA trial 
Metallic 
Biotronik AG 
(Germany) 
DREAMS Paclitaxel No 
(expected 
in 2016) 
No BIOSOLVE-II study 
Sources: manufacturers, fiercemedicaldevices.com, clinicaltrials.gov 
 
B0002 – What is the claimed benefit of the BVS in relation to other 
revascularisation techniques? 
Compared with CABG, which is an open heart surgery, the implantation of a 
stent is less invasive and, thus, associated with lower periprocedural risks [10]. 
However, in contrast to acute MI, where stent stents improve the prognosis 
of patients significantly, in patients with stable CAD, stents primarily reduce 
the symptoms of angina while they do not necessarily prolong life expectan-
cy or reduce the rate of MIs [11]. Furthermore, the problem with stents is 
that they induce in-stent neointimal hyperplasia, which can result in reste-
nosis and the need for repeated PCI. While DES have been more successful 
in avoiding restenosis than BMS, their greater risk of late stent thrombosis 
(> 30 days) has raised safety concerns leading to the development of a fur-
ther generation of DES using novel anti-proliferative agents, thinner stent 
struts and biocompatible or biodegradable polymers to minimise inflamma-
tion and improve the safety profile [2, 3].  
The latest developments are fully BVS. The currently CE-marked products 
resorb in several stages (hydration of the polymer, depolymerisation by hy-
drolysis, diffusion of short polymer chains into the body, assimilation of the 
small particles by phagocytes, conversion into dioxide and water, excretion 
through kidney or lungs) [12]. They are intended to combine the advantages 
of both, BMS and DES. Thus, they may reduce the risk of late thrombosis by 
leaving patients with a treated vessel free of a permanent stent implant. Fur-
thermore, patients need to take anti-platelet medication after stent implan-
tation, and it has been hypothesised [1] that duration of this therapy may be 
shorter after implanting a BVS in comparison to permanent stents. However, 
some patients may still need long term anti-platelet therapy because of their 
Vorteil von Stents 
gegenüber Bypass: 
weniger Risiko bei 
Intervention, aber ... 
 
... Restenose und späte 
Stentthrombosen 
möglich 
BVS sollen späte 
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ermöglichen später 
Bypass 
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underlying heart condition [1]. Moreover, further invasive therapies (e.g., 
CABG) will be easier in stent-free vessels and the material allows non-inva-
sive imaging (e.g., stent assessment with coronary computer tomography). 
Finally, BVS may be more acceptable by patients because of their preference 
for a temporary implant rather than a permanent one [1].  
 
B0003 – What is the phase of development and implementation  
of the BVS and of the other revascularisation techniques? 
In terms of CABG, the technology was first used in the1960s and has under-
gone continued advances, in particular with the systematic use of arterial con-
duits [7]. Implantations of BMS were first reported in 1986. The first DES 
was launched in 2003. Stenting has become a standard in coronary interven-
tion and DES have accounted for at least two thirds of the implanted stents. 
In 2010, the first BVS (ABSORB®) was approved in Europe and has increas-
ingly been used since then [1].  
 
Administration, investments, personnel and  
tools required to use the BVS and other stent types? 
B0004 – Who administers the use of revascularisation technologies in 
CAD and in what context and level of care are they provided? 
According to expert information, implanting a BVS requires the same infra-
structure, personnel and equipment as implanting other types of stents. How-
ever, implantation of a BVS requires a better preparation of the lesions. Fur-
thermore, because of limited possibilities of device expansion, the dimensions 
of the affected vessel must be exactly known, which will require invasive im-
aging more often [13]. The procedure is done in hospitals with an average 
duration of stay of three to four days. CABG is an open heart surgery that is 
also done in hospitals, yet it requires a longer hospital stay followed by re-
habilitation.  
 
B0008 – What kind of special premises are needed to use 
revascularisation technologies in CAD? 
PCI and stenting procedures require a cardiac catheterisation lab and a team 
consisting of interventional cardiologist, assistant nurses and radiology assis-
tants.  
Coronary artery bypass grafting is an open surgery and requires an operating 
theatre, usually a cardiopulmonary bypass (heart-lung-machine) and an in-
tensive care unit. Concerning personnel, surgeons, nurses, cardio-technicians 
and anaesthesiologists are required. 
 
B0009 – Which supplies are needed to use  
revascularisation technologies in CAD? 
According to the information from clinical experts, in terms of equipment for 
PCI and stenting, introducer needles, sheath introducers, guiding catheters, 
balloon catheters and coronary guidewires are needed. Specific imaging tech-
nologies (intravascular ultrasound or optical coherence tomography) are oc-
casionally necessary. Materials for general anaesthesia, sternotomy and sew-
ing material along with chest tubes are required for CABG. 
 
Revaskularisierung 
kontinuierlich 
weiterentwickelt 
BVS braucht  
selbe Infrastruktur  
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Regulatory & reimbursement status  
A0021 – What is the reimbursement status of the BVS? 
PCI and stenting are hospital based procedures and are therefore reimbursed 
via the Austrian DRG-system (Leistungsorientierte Krankenanstaltenfinan-
zierung/LKF). While BMS and DES are specified in the publicly financed 
benefit catalogue and therefore completely reimbursed per procedure, the 
BVS has not received a separate code so far. Reimbursement is currently the 
same as for DES. Because of the higher costs for BVS (according to infor-
mation from the manufacturer of the ABSORB®-stent, the price per device is 
€ 825 for Austria), reimbursement will very likely currently not cover the full 
costs.  
 
BVS derzeit nicht  
in MEL-Katalog, 
Vergütung als 
herkömmlicher Stent 
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3 Health Problem and Current Use 
3.1 Methods 
Research questions 
Element ID Research question 
Importance 
2=critical 
1=optional 
A0001  For which health conditions, and for what purposes are BVS used? 2 
A0002  What is the disease or health condition in the scope of this assessment?  2 
A0003  What are the known risk factors for CAD? 2 
A0004  What is the natural course of CAD? 2 
A0006  What are the consequences of CAD for society? 2 
A0024  How is CAD currently diagnosed according to published guidelines  
and in practice? 
1 
A0025  How is CAD currently managed according to published guidelines  
and in practice? 
2 
A0007  What is the target population in this assessment? 2 
A0023  How many people belong to the target population? 1 
A0011  How much are BVS utilised? 1 
 
Sources 
The primary sources for this chapter are guidelines on the diagnosis and man-
agement of CAD which have been retrieved via handsearch [5-7]. Addition-
ally, data from the Austrian health statistics [14], from international bodies 
[15] and manufacturer information have been used.  
 
 
3.2 Results 
Overview of the disease or health condition 
A0001 – For which health conditions, and for what purposes  
are BVS used? 
Just like coronary BMS or DES, BVS are indicated in patients with CAD. Yet, 
certain patients have been deemed unsuitable for the use of BVS, including 
those with extensive calcifications, with stenoses with large side branches 
and very large (>4 mm) or small (<2.5 mm) vessels [2]. This is because strut 
thickness was increased in order to keep the mechanical strength of a con-
ventional stent, and this negatively affects stent deliverability [4].  
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A0002 – What is the disease or health condition in the scope  
of this assessment?  
CAD which is a manifestation of atherosclerosis of the coronary arteries in-
cludes chronic (stable angina) and acute forms (acute coronary syndrome/ 
ACS). ACS summarises all phases of CAD that are immediately life threat-
ening (e.g. unstable angina, myocardial infarction, heart failure) [5].  
CAD remains the most common cause of death in industrialised countries. 
Similarly, ischaemic heart disease and acute myocardial infarction in particu-
lar are the leading causes of death in Austria, accounting for 12.5 % (9,961) 
and 6.1 % (4,876) of all deaths in 2013 respectively [14]. The number of cor-
onary events (myocardial infarction and cardiac death) is higher in males than 
in females and shows a social gradient [5].  
 
A0003 – What are the known risk factors for CAD? 
Known risk factors for CAD are hypertension, smoking, sedentary lifestyle, 
unhealthy diet, obesity, diabetes, genetic factors (family history) and abnor-
mal lipid metabolism [5, 6].  
 
Effects of the disease or health condition  
on the individual and society 
A0004 – What is the natural course of CAD? 
Patients with stable CAD have an elevated risk of myocardial infarction and 
premature mortality. The individual risk depends on different risk factors. 
It is higher in patients with co-morbidity (particularly diabetes) and with se-
vere forms and longer history of angina [5]. Estimates for annual mortality 
rates range from 1.2–2.4 % per annum with an annual incidence of cardiac 
death between 0.6 and 1.4 % and of non-fatal myocardial infarction between 
0.6 and 2.7 % [6].  
Additionally, angina is associated with recurring discomfort, impaired quality 
of life, reduced physical endurance, mental depression and recurrent hospi-
talisation [7].  
 
A0006 – What are the consequences of CAD for society? 
CAD has major human as well as economic costs. According to the European 
Cardiovascular Disease Statistics [15], CAD accounted for 2 % (€ 489,609,000) 
of the total health care expenditure or for € 59 per capita in 2009 in Austria. 
The biggest share (73 %) was attributed to inpatient care (€ 358,277,000).  
In Europe, the overall costs for CAD (including direct costs, productivity 
losses and informal care costs) have been estimated at over € 60 billion.  
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Current clinical management of the disease or health condition 
A0024 – How is CAD currently diagnosed according to  
published guidelines and in practice? 
Different diagnostic approaches are used for the chronic and the acute forms 
of the disease. 
The diagnosis and assessment of stable CAD involves clinical evaluation, in-
cluding identifying significant dyslipidaemia, hyperglycaemia or other bio-
chemical risk factors and specific cardiac investigations such as stress testing 
or coronary imaging. These investigations may be used to confirm the diag-
nosis of ischaemia in patients with suspected stable CAD, to identify or ex-
clude associated conditions or precipitating factors, assist in stratifying risk 
associated with the disease and to evaluate the efficacy of treatment. In prac-
tice, diagnosis and prognostic assessments are conducted simultaneously, ra-
ther than separately, and many of the investigations used for diagnosis also 
offer prognostic information [6]. 
In acute coronary situations, the diagnosis may include clinical evaluation, 
electrocardiogram, laboratory tests/biomarker and imaging (especially echo-
cardiography). The aim is to differentiate between non-ST-elevation myocar-
dial infarction/NSTEMI or ST-elevation-myocardial infarction/STEMI [8, 9].  
 
A0025 – How is CAD currently managed according to  
published guidelines and in practice? 
As in the diagnosis, the management of CAD depends on the clinical presen-
tation of CAD (stable, acute), on patient characteristics (age, co-morbidities, 
etc.) and related risk prognoses and on patient preferences [7]. 
In patients with stable CAD, management decisions after the diagnosis de-
pend on the severity of symptoms, on the patient’s risk factors for adverse 
cardiac events and on patient preferences. The choice is between preventive 
medication plus symptomatic medical management only or, additionally, re-
vascularisation, in which case the type of revascularisation has to be deter-
mined [6]. Any strategy needs to be accompanied by recommendations for 
life-style modification [5]. 
Indications for revascularisation are the persistence of symptoms despite med-
ical treatment and/or improvement of prognosis [7]. Patient preferences need 
to be taken into account [5]. In terms of revascularisation, whether PCI or 
CABG is preferred, should depend on the risk-benefit ratios of these treatment 
strategies, weighing the risks of procedural death, myocardial infarction and 
stroke against improvements in health-related quality of life, as well as long-
term freedom from death, myocardial infarction or repeat revascularisation. 
Decisions on the most appropriate revascularisation procedure should be 
guided by clinical judgement, multidisciplinary dialogue and patient prefer-
ences. Decisions may be supported by risk stratification models [7]. In gen-
eral, whether PCI or CABG is more appropriate very much depends of the 
type and number of affected vessels [5]. 
In patients with acute coronary syndrome, management depends on whether 
patients suffer from NSTEMI or from STEMI [7-9].  
In patients with NSTEMI (the most frequent manifestation of ACS), treat-
ment includes anti-ischemic therapy (nitrate, beta-receptor blocker etc.), an-
ti-platelet therapy and – potentially – invasive revascularisation. The latter 
depends on the potential risks associated with invasive and pharmacological 
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treatments [7]. In the case of a risk stratification that favours revascularisa-
tion, early routine angiography followed by revascularisation is favoured 
against a selective invasive strategy [7, 8]. In stabilised patients, the choice of 
the revascularisation modality can be made in analogy to patients with stable 
CAD [7, 8]. 
In the management of patients with STEMI, the timely implementation of 
reperfusion therapy (fibrinolysis, mechanical reperfusion by primary PCI) is 
the key issue [7, 9]. PCI (without prior fibrinolysis) has replaced fibrinolysis 
as the preferred reperfusion strategy, provided it can be performed in a timely 
manner in high-volume PCI centres with experienced operators [7, 9]. Stent-
ing should be preferred over plain balloon-angioplasty, and new-generation 
DES have been found to be more effective and safer than BMS [7]. In settings 
where a timely PCI cannot be performed, fibrinolysis should be considered, 
particularly if it can be administered pre-hospital [9]. After fibrinolysis, ear-
ly invasive evaluation is recommended [7]. 
In general, patients need to undergo antithrombotic treatment after revascu-
larisation. The choice, initiation, combination and duration of antithrombotic 
treatment depend on various factors (e.g., mode of revascularisation) [7]. 
Furthermore, myocardial revascularisation must always be accompanied by 
medical therapy and other secondary prevention strategies for risk factor mod-
ification and permanent lifestyle changes [7]. 
 
Target population 
A0007 – What is the target population in this assessment? 
The target population in this assessment includes patients with CAD due to de 
novo lesions of coronary arteries in whom antithrombotic and/or anticoagu-
lation therapy is not contra-indicated and who do not have aspirin, heparin, 
bivalirudin, clopidogrel, ticlopidin, prasugrel, ticagrelor, everolimus, PLLA, 
PDLLA, platin or contrast agent intolerance. 
According to a guideline from one Austrian clinic on the use of BVS, the pri-
mary group of patients includes those who are younger than 75, diabetic and 
with acute coronary syndromes (particularly with “soft-plaques”). The rec-
ommended vessel diameter is 2.5–3.5 mm. The recommended length of the 
lesion was initially short. In the meantime, the stent has been recommended 
for longer lesions (e.g. up to 48 mm in the first RCT [16]) to avoid a “full-
metal-jacket” and to restore vasomotion. Vessels should only show moderate 
calcification and should not have strong angulation (< 90°). 
 
A0023 – How many people belong to the target population?  
The size of the target group can only be approximated. As stable CAD is 
multi-faceted, its prevalence and incidence have been difficult to assess and 
numbers vary between studies. The prevalence of angina in population-based 
studies increases with age in both sexes, from 5–7% in women aged 45–64 
years to 10–12% in women aged 65–84 and from 4–7% in men aged 45–64 
years to 12–14% in men aged 65–84 years [6]. According to Austrian demo-
graphic data [17], these would be equal to 70,730 and 79,460 women aged 
45–64 and 65–84 years respectively, and to 63,560 and 74,245 men aged 45–
64 and 65–84 years respectively in Austria (~300,000 overall).  
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As pointed out above, a PCI is indicated only in some patients with stable 
CAD. Where decisions have been made in favour of a PCI, not all patients 
are eligible for a BVS.  
With respect to ACS, in 2005 around 24,000 discharges with an ICD-10 di-
agnosis referring to acute coronary syndrome occurred in Austria in patients 
up to 75 years. Additionally, around 16,000 revascularisation procedures were 
reimbursed (80% PCI) in this age group [18]. It is likely that the frequency 
of revascularisation has risen since then. A proportion of such procedures 
would in future include implanting a BVS (see next paragraph). 
 
A0011 – How much are the BVS utilised? 
According to the information provided by three hospital providers, the annual 
Austrian frequency is estimated at 2,000 to 6,000 BVS-procedures. The latter 
figure seems more realistic, since the three providers themselves already es-
timated annual frequencies of 230, 400 and 800 BVS-procedures respectively 
for their individual hospitals.  
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4 Clinical effectiveness 
4.1 Methods 
Research questions 
Element ID Research question 
Importance 
2= critical 
1=optional 
D0001  What is the expected beneficial effect of the BVS on mortality? 2 
D0003 What is the effect of the BVS on the mortality due to causes other 
than the target disease? 
2 
D0005 How does the BVS affect symptoms and findings (severity, frequency) 
of the disease or health condition? 
2 
D0006  How does the BVS affect recurrence of the disease or health condition? 2 
D0016 How does the use of the BVS affect activities of daily living? 2 
D0012 What is the effect of the BVS on generic health-related quality of life? 2 
D0013 What is the effect of the BVS on disease-specific quality of life? 1 
D0017  Was the use of the BVS worthwhile?  1 
 
The following crucial outcomes were used as evidence to derive a  
recommendation: 
 (Cardiac) mortality 
 Morbidity: symptoms of angina, MI 
 Health-related quality of life 
 Recurrent revascularisation 
Revascularisation procedures in patients with CAD are applied to minimise the 
risk of premature cardiovascular death and to reduce the symptoms of CAD. 
Hence, the crucial patient relevant outcomes to evaluate the efficacy of any 
revascularisation technique including BVS are (cardiac) mortality, cardiac 
morbidity in terms of symptoms of angina or MI and health-related quality of 
life. This is also supported by the guideline of the European HTA network [19], 
which points out that endpoints should be long-term or final and all-cause mor-
tality is a preferred clinical endpoint when relevant for the scope of assessment.  
As described in Chapter 2.2, one problem with conventional stents is the need 
for repeated revascularisation because of re-stenosis. Hence, revascularisation 
frequency after the implantation has been selected as the fourth crucial out-
come. 
One endpoint often used in studies on revascularisation is the composite end-
point “major adverse cardiac events” (MACE). However, according to the 
EUnetHTA guideline [19], composite endpoints should be avoided for eval-
uating a technology because the combination often consists of endpoints with 
very different clinical importance. Instead, a composite endpoint should be 
disaggregated to the constituent endpoints. In our case, the composite end-
point MACE is inappropriate for the evaluation for two reasons: firstly, MACE 
is defined differently across studies; secondly, it combines efficacy and safe-
ty endpoints. Consequently, the composite endpoint itself was not chosen as 
relevant outcome parameter, but rather its components.  
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Sources 
The evidence used in this chapter is based on a systematic literature search 
in the Medline via Ovid, Embase, Cochrane Library, and CRD (DARE – NHS 
EED – HTA) databases, and is complemented by a hand search and manu-
facturer requests according to the PICO question defined in Chapter 1.2. 
 
Analysis 
The data retrieved from the selected studies (see Chapter 1.4) were systemat-
ically extracted into a data-extraction-table (Table A1-1). No further data 
processing (e.g., indirect comparison) was applied. The studies were system-
atically assessed for quality and risk of bias using the checklists presented in 
the Tables A2-1 and A2-4. 
 
Synthesis 
Based on the data-extraction-table (Table A1-1), data on each selected out-
come category were synthesised across studies according to GRADE (Grading 
of Recommendations Assessment, Development and Evaluation) [20]. The 
results were summarised in evidence-tables (Table 6-1, Table 6-2). The re-
search questions were answered in plain text format.  
 
 
4.2 Results 
Included studies 
For evaluating the efficacy of the BVS ABSORB®, 12-months interim results 
from one RCT with 501 participants [16] and nine-months interim results from 
an RCT with 240 patients were available. Overall, 415 patients received the 
BVS (ABSORB®) and 326 a DES (166 Xience Prime®/Everolimus, 80 Promus 
Element®/Everolimus, 80 Biomatrix Flex®/Biolimus). Study participants were 
predominantly male with an average age of 61 to 65 years suffering from 
chronic CAD or ACS (at least one to two de novo lesions affected). Details on 
anti-platelet therapy were provided in one study: a combination of aspirin 
(≥100 mg) lifelelong plus either clopidogrel, prasugrel or ticagrelor for at 
least 6 months was prescribed. 
No evidence was available to evaluate the efficacy of the ABSORB® in com-
parison to other revascularisation technologies and to evaluate the efficacy of 
the second product with CE-marking (DESolve®). 
Study characteristics and results of included studies are displayed in Table 
A1-1 and summarised inTable 6-1 and Table 6-2. 
 
 
 
Daten aus 
systematischer Suche  
+ weiteren Quellen 
Analyse basiert auf 
Datenextraktionstabellen 
und risk of bias Analyse 
Evidenzsynthese  
mittels GRADE 
ABSORB®:  
2 RCTs 
Clinical effectiveness 
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Mortality 
D0001 – What is the expected beneficial effect of the BVS on mortality? 
Within nine to 12 months follow-up, there was one cardiac death in the BVS 
group and no cardiac death in the DES groups. The difference is not statisti-
cally significant. 
 
D0003 – What is the effect of the BVS on the mortality due to  
causes other than the target disease? 
Within nine to 12 months follow-up four persons (1 %) in the control group 
died. One death was due cancer; in the other three cases, the causes were not 
mentioned. There was no death due to causes other than CAD in the BVS 
group. The difference is not statistically significant. 
 
Morbidity 
D0005 – How does the BVS affect symptoms and findings  
(severity, frequency) of the disease or health condition? 
Within nine to 12 months 16 (4%) patients in the BVS groups versus three 
(1%) in the DES groups had a myocardial infarction. In none of the studies, 
the difference was statistically significant. Furthermore, three quarters in each 
group of the 12-months study (227 vs. 113) were angina-free (p=0.98). A post-
hoc analysis showed a cumulative angina rate of 72 (22%) in the BVS group 
and of 50 (30%) in the DES group (p=0.04).  
 
D0006 – How does the BVS affect recurrence of  
the disease or health condition? 
Within nine to 12 months, 4% to 24% of patients who received the BVS and 
7% to 39% of patients who received a DES needed to undergo revascularisa-
tion. The difference is not statistically significant in either of the RCTs. 
 
Function 
D0016 – How does the use of the BVS affect activities of daily living? 
No evidence was found to answer the research question. 
 
Health-related quality of life 
D0012 – What is the effect of the BVS on generic health-related quality 
of life? 
Data on the quality of life were incompletely presented. The difference be-
tween the groups in terms of health-related quality of life was not significant 
(p=0.55). 
 
1 kardialer Tod in BVS 
4 Tote in  
DES-Gruppe 
Infarkte und Angina-frei: 
kein Unterschied zu DES; 
geringere Angina-Rate 
in BVS-Gruppe 
Revaskularisierung:  
kein Unterschied zu DES 
Alltagsaktivitäten:  
keine Evidenz 
Lebensqualität:  
kein Unterschied 
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5 Safety 
5.1 Methods 
Research questions  
Element ID Research question 
Importance 
2=critical 
1=optional 
C0008  How safe is the BVS in comparison to other stent types or other 
revascularisation techniques? 
2 
C0002 Are the harms related to dosage or frequency of applying the 
technology? 
1 
C0004 How does the frequency or severity of harms change over time or in 
different settings? 
1 
C0005 What are the susceptible patient groups that are more likely to be 
harmed through the use of the technology? 
1 
C0007 Are the technology and comparator(s) associated with user-dependent 
harms? 
1 
B0010 What kind of data/records and/or registry is needed to monitor the use 
of the BVS and the other revascularisation techniques? 
1 
 
The following crucial outcomes were used as evidence to derive a  
recommendation: 
 Scaffold/stent-thrombosis and adverse consequences 
 Mortality: periprocedural mortality, mortality from bleeding/stroke 
 Other serious adverse events (e.g., stroke) 
Compared to CABG, one potential advantage of revascularisation with PCI 
and stent is its lower periprocedural risk. However, stents, in particular first 
generation DES, have been associated with increased long-term risk of stent 
thrombosis, which is itself related to increased risk of cardiovascular mor-
bidity and mortality. Furthermore, the anti-platelet therapy patients need to 
undergo after stenting bears the risk of severe bleeding and mortality. Conse-
quently, scaffold/stent thrombosis, periprocedural mortality and/or mortality 
from bleeding/stroke have been chosen as crucial safety outcomes.  
 
Sources 
The evidence used in this chapter is based on a systematic literature search 
in the Medline via Ovid, Embase, Cochrane Library and CRD (DARE – NHS 
EED – HTA) databases, complemented by a hand search and manufacturer 
requests according to the PICO-question defined in Chapter 1.2. 
 
 
entscheidende 
Sicherheits-Outcomes 
Begründung:  
BVS sollten geringeres 
Re-Interventions- und 
spätes Thromboserisiko 
haben 
Daten aus 
systematischer Suche  
+ weiteren Quellen 
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Analysis 
The data retrieved from the selected studies (see Chapter 1.4) were systemat-
ically extracted into data-extraction-tables (Table A1-1, A1-2). No further data 
processing (e.g., indirect comparison) was applied. The studies were system-
atically assessed for quality and risk of bias using the checklists presented in 
the Tables A2-1, A2-2, A2-3 and A2-4.  
 
Synthesis 
Based on the data-extraction-tables (Table A1-1, A1-2), data on each selected 
outcome category were synthesised across studies according to GRADE (Grad-
ing of Recommendations Assessment, Development and Evaluation) [20]. The 
results were summarised in evidence-tables (Table 6-1, Table 6-2). The re-
search questions were answered in plain text format.  
 
 
5.2 Results 
Included studies 
For evaluating the safety of the BVS ABSORB®, in addition to the RCTs [16, 
21] described in Chapter 4.2., ten observational studies presented in 13 pub-
lications [22-34] fulfilled our inclusion criteria. Eight studies (eleven publi-
cations) [22-32] were single arm and the remaining two [33, 34] were non-
randomised controlled studies.  
Overall, safety data were available from 1,290 patients with BVS and from 
486 patients with traditional stents (mainly DES). 364 (30%) BVS-patients 
suffered from acute coronary syndrome, 740 (61%) from stable CAD, and 186 
(15%) from either the former or the latter. 166 DES-patients suffered from 
stable CAD, 160 from acute coronary syndrome and 160 from either the for-
mer or the latter. The follow-up ranged from one month (three studies), six 
months (four studies) and nine months (one study) to 12 months (three stud-
ies) and 36 months (one study). 
Patients were on average around 60 to 65 years old and were predominantly 
male (70-80%). If anti-platelet therapy was described, it was a combination 
of aspirin (≥75 to 100 mg) plus either clopidogrel, prasugrel or ticagrelor for 
at least 12 months. 
For evaluating the safety of the DESolve®, one single-arm observational study 
fulfilled the inclusion criteria [35]. It is a small (16 patients) uncontrolled case 
series that evaluates a myolimus-eluting BVS prototype, while the product 
that is currently on sale elutes novolimus. The patients were on average 69 
years old and 63% were male.  
Study characteristics and results of included studies are displayed in Tables 
A1-1 and A1-2 and summarised in Tables 6-1 and 6-2. 
 
Analyse basiert auf 
Datenextraktionstabellen 
und risk of bias Analyse 
Evidenzsynthese  
mittels GRADE 
ABSORB®: 2 RCTs +  
10 Beobachtungsstudien, 
primär einarmig 
mehrheitlich 
PatientInnen mit 
stabiler KHK 
 
Nachbeobachtung  
1 bis 36 Monate 
ø 60–65 Jahre,  
primär männlich 
DESolve®:  
16 PatientInnen  
in einarmiger  
Prototyp-Studie  
Safety 
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Patient safety 
C0008 – How safe is the BVS in comparison to  
other stent types or other revascularisation techniques? 
ABSORB® 
In four studies with a follow-up of six months [26, 30, 32, 33] scaffold throm-
bosis was observed in four (1.3%) patients. In a nine-month follow-up study 
one scaffold thrombosis occurred. In three studies with a follow-up of 12 
months [16, 27, 31], scaffold thrombosis was observed in another four pa-
tients (0.6%). No scaffold thrombosis appeared in the 36 patients with 36 
months follow-up [25]. No stent thrombosis occurred in any of the patients 
in the comparison groups. Where stated, the differences between the groups 
were not statistically significant. 
Where reported, two BVS-patients and two DES-patients died periprocedur-
ally (0.2% and 0.6% respectively) [30, 33, 34].  
One patient in the BVS groups versus no patient in the DES groups died from 
bleeding due to anti-platelet therapy [27].  
Stroke or pneumonia were observed in nine patients (2%) in the BVS groups 
and in two patients (2%) in the stent groups [27, 30, 32, 34]. 
No evidence on the safety of the BVS in comparison to other revascularisation 
techniques is available. 
 
DESsolve® 
In the 16 patients who received a prototype of the DESolve® scaffold, one 
adverse event occurred: one death following a non-target vessel CABG [35].  
 
C0002 – Are the harms related to the frequency of  
applying the technology? 
In theory, the risk of harms increases with the number of scaffolds or stents 
implanted. The included studies did not analyse whether the frequency of 
harms was associated with the number of scaffolds implanted. 
 
C0004 – How does the frequency or severity of  
harms change over time or in different settings? 
Interventional cardiology requires experienced teams. However, whether any 
harms were associated with volumes of the involved centres or with learning 
curves has not been part of the research question in the studies.  
 
C0005 – What are the susceptible patient groups  
that are more likely to be harmed through the use of the technology? 
The periprocedural deaths described above occurred in patients with acute 
coronary syndrome compared to no periprocedural deaths in patients with 
stable CAD. However, whether or not this was a coincidence cannot be judged 
on the basis of the current evidence.  
 
<1,5 % Thrombosen  
in BVS-, 0 % in  
DES-PatientInnen 
periprozeduraler Tod  
<1 % in beiden Gruppen 
Blutungstod: 1 vs. 0  
jeweils 2 % andere 
schwere Ereignisse 
Sicherheit gegenüber 
Bypass unklar 
1 Tod in DESolve® 
Studie 
Zusammenhang Anzahl 
Implantate-Schaden 
nicht analysiert 
Zusammenhang 
Erfahrung/Menge-
Schaden nicht analysiert 
ob höheres Risiko  
bei akutem Syndrom 
noch unklar  
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C0007 – Are the technology and comparator(s) associated  
with user-dependent harms? 
The accompanying angiography may result in contrast-induced nephropathy 
which was a reported outcome in one study [26]. Where reported, none of the 
patients (out of 33) experienced a contrast-induced nephropathy.  
 
Investments and tools required 
B0010 – What kind of data/records and/or registry is needed to monitor 
the use of the BVS and the other revascularisation techniques? 
Firstly, the superior benefit-harm profile of the BVS needs to be demonstrated 
in robust randomised controlled trials. Indeed, a large number of RCTs are 
currently ongoing (see Table A4-1 in the Appendix). Because late and very 
late scaffold thromboses cannot easily be observed in RCTs, registries are ad-
ditionally recommended to monitor safety. A large number of registries have 
already be established (see Table A1-2 and Table A4-1) and should be con-
tinued [27]. Results from those can be expected from 2016 onwards.  
 
keine Nephropathie 
durch Kontrastmittel, 
aber kaum berichtet 
RCTs und Register nötig, 
viele laufen bereits 
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6 Quality of evidence 
The strength of evidence for each endpoint was individually rated according 
to the GRADE (Grading of Recommendations Assessment, Development and 
Evaluation) scheme [20]. Each study was rated by two independent research-
ers. In case of disagreement, a third researcher was involved to solve the dif-
ference. A more detailed list of applied criteria can be found in the recom-
mendation of the GRADE Working Group [20]. The ranking according to the 
GRADE scheme for the research question can be found in the Table 6-1 and 
Table 6-2.  
GRADE uses four categories to rank the strength of evidence: 
 High = We are very confident that the true effect lies close to that  
of the estimate of the effect;  
 Moderate = We are moderately confident in the effect estimate:  
The true effect is likely to be close to the estimate of the effect, but 
there is a possibility that it is substantially different;  
 Low = Our confidence in the effect estimate is limited: The true ef-
fect may be substantially different from the estimate of the effect;  
 Very low = Evidence either is unavailable or does not permit  
a conclusion. 
In outcomes based on randomised controlled trials, the rating starts with 
“high”, however the strength of evidence may be downgraded for several rea-
sons (see GRADE methodology [20]). In observational studies the rating starts 
with low because the study design of such trials is per se limited with respect 
to judging on efficacy or safety. The strength of evidence may be downgrad-
ed further or upgraded depending on further criteria applied (see Table 6-1 
and Table 6-2 and recommendation of the GRADE Working Group [20]). 
The strength of evidence for the effectiveness of the BVS ABSORB® in CAD 
in comparison to three types of DES is moderate for the outcomes “(all-
cause-)mortality”, “morbidity (myocardial infarction, angina)” and “quality 
of life”. Moreover, the strength of evidence for the outcome “revascularisa-
tion” is high for a nine-month follow up and low for a 12-month follow-up. 
The strength of evidence for the safety of BVS ABSORB ® in comparison to 
three types of DES in patients with CAD is moderate for short term scaffold/ 
stent thrombosis. For all other safety outcomes the strength of evidence is 
very low. Likewise very low is the strength of the evidence for the safety of 
the BVS DESolve®. 
No evidence is available for the comparison of BVS and CABG.  
 
 
Qualität der Evidenz 
nach GRADE 
Schema für Beurteilung 
Bewertung beginnt  
mit „hoch” bei RCTs  
und mit „niedrig“ bei 
Beobachtungsstudien  
Stärke der Evidenz 
Wirksamkeit ABSORB®: 
mittel 
Stärke der Evidenz 
Sicherheit ABSORB® und 
DESolve®: moderat bis 
sehr niedrig 
andere Vergleiche:  
keine Evidenz 
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Table 6-1: Evidence profile: efficacy and safety of bioresorbable scaffold ABSORB® in patients with coronary artery disease 
No of  
studies/patients Study Design Estimate of effect Study limitations Inconsistency Indirectness 
Other  
modifying factors 
Strength  
of evidence 
Efficacy 
All-cause mortality  
1/240 
 
1/501 
RCT 
 
RCT  
9 months: 1 (1 %) vs.  
3 (2 %)2; p=1.00 
12 months: 0 vs.  
1 (1 %); p=0.33 
No serious limitations 
 
No serious limitations 
Only 1 trial 
 
Only 1 trial 
Direct, no uncertainty 
 
Direct, no uncertainty 
Imprecise data3 (-1) 
 
Imprecise data3 (-1) 
Moderate 
 
Moderate 
Cardiac mortality  
1/240 
 
1/501 
RCT 
 
RCT 
9 months: 1 (1 %) vs.  
0; p=0.33 
12 months: 0 vs. 0 
No serious limitation 
 
No serious limitations 
Only 1 trial 
 
Only 1 trial 
Direct, no uncertainty 
 
Direct, no uncertainty 
Imprecise data3 (-1) 
 
Imprecise data3 (-1) 
Moderate 
 
Moderate 
Myocardial infarction  
1/240 
 
1/501 
RCT 
 
RCT 
9 months: 1 (1 %) vs.  
1 (1 %); p=0.55 
12 months: 15 (4 %) vs. 
2 (1 %); p=0.06 
No serious limitations 
 
No serious limitations 
Only 1 trial 
 
Only 1 trial 
Direct, no uncertainty 
 
Direct, no uncertainty 
Imprecise data3 (-1) 
 
Imprecise data3 (-1) 
Moderate 
 
Moderate 
Angina-free 12 months 
1/501 RCT 74 % vs. 74 %; p=0.98 Serious limitations4 (-1)  Only 1 trial Direct, no uncertainty No Moderate 
Angina rate 12 months 
1/501 RCT 22 % vs. 30 %; p=0.04 Serious limitations5 (-1) Only 1 trial Direct, no uncertainty No Moderate 
Quality of life 12 months 
1/501 RCT na (p=0.55) Serious limitations4 (-1) Only 1 trial Direct, no uncertainty No Moderate 
Revascularisation  
1/240 
 
1/501 
RCT 
 
RCT 
9 months: 19 (24 %) vs. 
39 (24 %); p=0.99 
12 months: 12 (4 %) vs. 
12 (7 %); p=0.08 
No serious limitation 
 
Serious limitations6 (-1) 
Only 1 trial 
 
Only 1 trial 
Direct, no uncertainty 
 
Direct, no uncertainty 
Imprecise data7 (-1) 
 
Imprecise data3 (-1) 
Moderate 
 
Low 
                                                             
2 Including one cardiac death presented in the following row 
3 Low incidence, study not powered to detect differences 
4 No blinding of outcome assessors, 11% of patients in BVS groups and 3% of patients in DES group were potentially unblinded 
5 No blinding of outcome assessors, 11% of patients in BVS groups and 3% of patients in DES group were potentially unblinded, post-hoc analysis 
6 No blinding of outcome assessors 
7 Study not powered to detect statistically significant differences 
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No of  
studies/patients Study Design Estimate of effect Study limitations Inconsistency Indirectness 
Other  
modifying factors 
Strength  
of evidence 
Safety 
Scaffold/stent thrombosis 6 months (definite or probable) 
6 months: 4/306 
9 months: 1/240 
12 months: 2/283 
12 months: 1/501 
36 months: 1/36 
Observational 
RCT 
Observational 
RCT 
Observational 
4 (1.3 %) vs. 0 
1 (1 %) vs. 0; p=0.33 
1 (1 %) vs. na 
3 (1 %) vs. 0; p=0.55 
0 vs. na 
Serious limitations8 (-1) 
No serious limitation  
Serious limitations9 (-1) 
No serious limitations 
Serious limitations10 (-1) 
No important inconsistency 
Only 1 trial 
No important inconsistency 
Only 1 trial 
Only 1 trial 
Direct, no uncertainty 
Direct, no uncertainty 
Direct, no uncertainty 
Direct, no uncertainty 
Direct, no uncertainty 
No 
Imprecise data3 (-1) 
No 
Imprecise data3 (-1) 
No 
Very low 
Moderate 
Very low 
Moderate 
Very low 
Periprocedural mortality 
10/1475  Observational 2 (0.2 %) vs. 2 (0.6 %) Serious limitations11 (-1) No important inconsistency Direct, no uncertainty No Very low 
Mortality from bleeding/stroke 
6 months: 2/175 
12 months: 2/283 
36 months. 1/101 
Observational 
Observational 
Observational 
0 vs. 0 
1 (0.4) vs. na 
0 vs. na 
Serious limitations12 (-1) 
Serious limitations12 (-1) 
Serious limitations10 (-1) 
No important inconsistency 
No important inconsistency 
Only 1 trial 
Direct, no uncertainty 
Direct, no uncertainty 
Direct, no uncertainty 
No 
No 
No 
Very low 
Very low 
Very low 
Other serious adverse events 
4/567 Observational 9 (2 %) vs. 2 (2 %) Serious limitations13 (-1) No important inconsistency Direct, no uncertainty No Very low 
BVS: bioresorbable vascular scaffold; na: data not available; significant values in bold 
 
                                                             
  8 In three studies no control group; treatment with BVS not pre-defined (e.g., according to decision of physician) 
  9 No control groups; high risk of selection bias because treatment with BVS not pre-defined 
10 No control group; deviance from study protocol 
11 In seven studies no control group; in five studies high risk of selection bias because treatment with BVS not pre-defined; in one study:  
analysis combines data from different studies; in 1 study deviance from study protocol 
12 In one study: high risk of selection bias because treatment with BVS not pre-defined (e.g., according to decision of physician) 
13 In three studies: no control group; in one study: treatment with BVS not pre-defined 
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Table 6-2: Evidence profile: efficacy and safety of bioresorbable scaffold DESolve® in patients with coronary artery disease 
No of 
studies/patients Study Design 
Estimate  
of effect Study limitations Inconsistency Indirectness 
Other  
modifying factors 
Strength  
of evidence 
Efficacy 
No evidence 
Safety 
Scaffold thrombosis (12 months) 
1/16 Observational 0 Serious limitations14 (-1) Only 1 trial Direct, no uncertainty Imprecise data (-1) Very low 
Periprocedural mortality (12 months) 
1/16 Observational 0 Serious limitations14 (-1) Only 1 trial Direct, no uncertainty Imprecise data (-1) Very low 
Mortality from bleeding/stroke (12 months) 
1/16 Observational 0 Serious limitaitons14 (-1) Only 1 trial Direct, no uncertainty Imprecise data (-1) Very low 
Other serious adverse events (12 months) 
1/16 Observational 1 (6 %)15  Serious limitations14 (-1)  Only 1 trial Direct, no uncertainty Imprecise data (-1) Very low 
 
 
                                                             
14 Unclear whether all consecutive patients were included 
15 Death following non-target vessel CABG 
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7 Discussion 
The currently available evidence (based on two RCTs) shows that concerning 
patient relevant outcomes the implantation of a BVS is not more efficacious 
than implanting a DES: After 12 months, (cardiac) mortality, MI, revascular-
isation and quality of life did not significantly differ between patients who 
received a BVS compared to those who received a DES. An equal proportion 
in both groups was free from angina. The cumulative angina rate was lower in 
the BVS than in the DES group; however, this is based on a post-hoc analysis. 
In terms of safety, there were in total nine short term scaffold thromboses di-
agnosed after BVS implantations, while no thrombosis was observed after DES 
implantation. However, the frequency of scaffold thrombosis was very low 
(<1.5 %). Less than 1 % of participants died from either periprocedural mor-
tality or from cardiovascular mortality in the intervention and control groups 
respectively. Except for thrombosis, the strength of the safety evidence is very 
low and long-term safety outcomes (especially very late scaffold thrombosis 
incidence) are currently unknown. 
In summary, while the current evidence suggests that the BVS is not superi-
or in terms of patient relevant benefits, it is unknown to date whether it is at 
least equally effective but safer than other stent technologies. 
The available evidence is almost entirely related to one of the two CE-marked 
products (ABSORB®), while the only available study on DESolve® is a very 
small-scale, uncontrolled case series, which does not evaluate the currently 
available product but rather a prototype. 
The quality of evidence is limited for several reasons. Firstly, while physi-
cians cannot be blinded in this case, patients and outcome assessors could 
be. However, either outcome assessors or patients were not blinded in the 
RCTs. This introduces a risk of bias for a number of crucial outcomes (e.g. 
quality of life, angina symptoms). Secondly, the primary endpoint in the RCT 
was a surrogate parameter. This means the RCT was not powered for detect-
ing statistically significant differences in the patient-relevant endpoints, so 
much the more, as many of the crucial outcomes rarely occur (e.g., cardio-
vascular mortality as a consequence of the implant). 
The most severe limitations in the observational studies are a lack of control 
groups in most of them and a high risk of selection bias because of the lack 
of a study protocol or because the decision on implantation of the BVS was 
based on physicians’ judgement. This could have resulted in implanting the 
BVS predominantly in patients with a good prognosis.  
Applicability of the results to routine patients is limited for the following 
reasons (see Table A3-1): Firstly, the patients in most of the studies were 
predominantly males with a mean age of around 60 years and with relatively 
simple lesions. Results are therefore not transferable to patients with com-
plex lesions with wider age ranges frequently encountered in daily practice, 
which has also been pointed out by study authors [16]. Furthermore, caution 
is required for transferring the results to females. In addition, most of the 
patients had stable angina pectoris and very few studies (most of them have 
a high risk of bias) included patients with acute coronary artery syndrome. 
The results are, therefore, predominantly valid for a population with stable 
CAD, while the benefit and safety of the BVS in patients with acute disease 
has yet to be robustly evaluated. 
nach derzeitiger 
Evidenz: BVS nicht 
wirksamer als DES  
unerwünschte 
Ereignisse selten,  
aber große 
Datenunsicherheit und 
fehlende Langzeitdaten 
endgültiges  
Nutzen-Schaden Profil 
noch unklar 
fast nur Daten für 
ABSORB® 
limitierte 
Studienqualität: 
Untersucher oder 
Patienten nicht 
verblindet, für relevante 
Outcomes zu geringe 
Studiengröße 
Beobachtungsstudien: 
meist einarmig,  
Gefahr Selektionsbias  
Gültigkeit für ältere 
PatientInnen mit 
komplexen Läsionen 
und akutem Syndrom  
und für Frauen 
eingeschränkt 
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Secondly, while the implantation procedure itself does not differ between clin-
ical study setting and routine use, patients in the studies underwent multiple 
imaging procedures. Adverse consequences of the scaffold may have there-
fore been better detected than it would be the case in routine care, but it could 
also have resulted in false-positive results or in negative consequences fol-
lowing the treatment decisions after the imaging results (e.g., adverse events 
after revascularisation following a positive re-stenosis diagnosis).  
Thirdly, the BVS was compared to three types of DES. In routine care, other 
stent types and other revascularisation strategies will play an important role. 
The performance of the BVS in comparison to those approaches has not been 
evaluated so far. 
Furthermore, in terms of scaffold thrombosis, the main interest is in late and 
very late (> 12 months) thrombosis. However, the results available at the mo-
ment are predominantly from a follow-up from six to maximum 12 months. 
Finally, while the setting in the studies has not been described precisely, most 
of the procedures seem to have been undertaken in highly specialised uni-
versity units. The transferability to a low-volume cardiac catheterisation lab 
with less experienced cardiologists may also be limited. 
 
 
Unterschied Bildgebung 
Studie-Routine 
Nutzen  
gegenüber anderen 
Revaskularisierungs-
methoden unklar 
späte Thrombosen bei 
derzeitiger Studiendauer 
kaum erkennbar 
Studien in 
spezialisierten Zentren 
durchgeführt 
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8 Recommendation 
In Table 8-1 the scheme for recommendations is displayed and the according 
choice is highlighted. 
Table 8-1: Evidence based recommendations 
 The inclusion in the catalogue of benefits is recommended.  
 
The inclusion in the catalogue of benefits is recommended with 
restrictions. 
X The inclusion in the catalogue of benefits is currently not recommended. 
 The inclusion in the catalogue of benefits is not recommended. 
 
Reasoning:  
The current evidence is not sufficient to prove that the BVS is more effective 
and safer or at least equally effective but safer than current stent technolo-
gies. No evidence exists to date whether the implantation of a BVS is more 
effective and/or safer than CABG. 
A very large number of studies (at least 14 RCTs and 20 single-arm studies, 
including the ongoing RCT that has been cited in this report [16]) are cur-
rently registered (see Chapter “Ongoing studies” of the Appendix for details). 
They include around 32,120 patients in total and will potentially influence 
the estimate of effect considerably:  
 ABSORB ®: ten RCTs (11,107 patients), one non-randomized  
controlled study (60 patients), nine single arm studies (registries) 
with 13,323 patients; an overall total of 24,514 patients 
 DESolve®: three single-arm studies with 342 patients 
 NeoVas: 1 RCT (560 patients), two single-arm studies (855 patients); 
1,415 patients overall 
 Fortitude: two single-arm studies (170 patients) 
 ReZolve: one single-arm study (125 patients) 
 ART18Z: one single-arm study (30 patients) 
 Biosolve: one single-arm study (121 patients) 
 Unspecified devices: three RCTs (2,140 patients), one single-arm  
registry (1,500 patients), one unspecified study-design (2,000 patients); 
an overall total of 5,640 patients 
A re-evaluation is recommended in 2018. While many of the studies listed in 
Chapter “Ongoing studies” of the Appendix will still be ongoing at that time, 
a number of interim results from RCTs and safety data from the registries 
will very likely be available by then. 
 
 
(noch) kein Beleg  
für besseres Nutzen-
Schadenprofil des BVS 
sehr viele laufende 
Studien 
neuerliche Evaluierung: 
2018 
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Appendix 
Evidence tables of individual studies included for clinical effectiveness and safety 
Table A1-1: Bioresorbable scaffolds: results from randomised controlled trials 
Trial, author, year,  
reference number ABSORB II; Serruys 2014 [16] EVERBIO II; Puricel 2015 [21] 
Country Europe, New Zealand Switzerland 
Sponsor Abbott Vascular Abbott Vascular, Biosensors International, Boston Scientific 
Intervention/Product Everolimus-eluting bioresorbable scaffold (Absorb®) Everolimus-eluting bioresorbable scaffold (Absorb®) 
Comparator Everolimus-eluting metallic stent (Xience®) Everolimus-eluting stent (Promus Element®/Boston Scientific) 
Biolimus eluting stent (Biomatrix Flex®/Biosensors) 
Study design RCT RCT 
Number of pts 501 (335 vs.166) 240 (80 vs. 80 vs. 80) 
Sex (% male) 76 vs. 80 78 vs. 80 vs. 80 
Inclusion criteria 18-85 years with evidence of myocardial ischaemia, 1 to 2 de-novo lesions 
in different epicardial vessels (max. ø 2.25-3.8; max. length 48 mm) 
≥18 years, symptomatic CAD or silent ischaemia; no limit for lesion 
length, number of target lesions or vessels; reference vessel size >4.0 mm 
Mean age of patients: yrs (SD) 61.5 (10) vs. 60.9 (10) 65 (11) vs. 65 (11) vs. 65 (10) 
Primary endpoint Vasomotion, Minimum Lumen Diameter (MLD) post nitrate minus 
MLD post procedure post nitrate 
LLL 
Follow-up (months) 36; this analysis: 12 60; this analysis: 9 
Loss to follow-up, n (%) 6 (2) vs. 2 (1) 9 (12) vs. 8 (10) vs. 5 (6) 
Anti-platelet therapy  na Loading dose of 600 mg clopidogrel, 180 mg ticagrelor or 60 mg 
prasugrel; lifelong ≥100 mg daily aspirin and 75 mg daily clopidogrel, 
90 mg twice daily ticagrelor or 10 mg prasugrel for min. 6 month 
Outcomes 
Efficacy 
All-cause mortality; n (%) 0 (0) vs. 1 (1)16 
-0.61 % (95 % CI: -3.35 to 0.65); p=0.33 
1 (1) vs. 3 (4) vs. 0; 
p EES/BES vs. BVS: 1.0 
Cardiac mortality; n (%) 0 vs. 0 1 (1) vs. 0 vs. 0 
Myocardial infarction17; n (%) 15 (4) vs. 2 (1) 
+3.32% (95% CI: -0.25 to 6.26); p=0.06 
1 (1) vs. 1 (1) vs. 0 
p EES/BES vs. BVS: 0.55 
                                                             
16 Due to cancer 
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Trial, author, year,  
reference number ABSORB II; Serruys 2014 [16] EVERBIO II; Puricel 2015 [21] 
Angina; n (%) Angina-free: 227 (74) vs. 113 (74); p=0.98 
Cumulative angina rate: 72 (22) vs. 50 (30); p=0.0418 
na 
Quality of life n: na 
p=0.55 
na 
Re-vascularisation 12 (4) vs. 12 (7) 
-3.65 % (95 % CI: -8.89 to 0.37) p=0.08 
19 (24) vs. 24 (30) vs. 15 (19) 
p EES/BES vs. BVS: 0.99 
Composite endpoint (death, MI, 
revascularisation); n (%) 
24 (7) vs. 15 (9) 
-1.84 % (95 % CI: -7.69 to 2.98); p=0.47 
21 (27) vs. 26 (33) vs. 15 (19) 
p EES/BES vs. BVS: 0.83 
Safety 
Overall complications; n (%) na  
Scaffold/stent thrombosis; n (%) Definite thrombosis 
Acute (0-1 day) 
1 (0.3) vs. 0; p=1 
Sub-acute (2-30 days) 
1 (0.3) vs. 0; p=1 
Late (31-365 days) 
0 vs. 0; p=1 
Overall definite or probable thrombosis 
3 (0.9) vs. 0; 
+ 0.91 % (95 % CI: -1.45 to 2.65); p=0.55 
1 (1) vs. 0 vs. 0 
p EES/BES vs. BVS: 0.33 
Periprocedural mortality, n (%)  0 vs. 0 na 
Periprocedural myocardial 
infarction; n (%) 
na (3-30) vs. na (1-26)19 
p=na 
na 
Bleeding from anti-platelet 
treatment 
na na 
Procedure-related  
contrast-induced nephropathy 
na na 
Vascular access-site complication na na 
Mortality from bleeding or stroke na na 
Other serious adverse events na na 
BES: biolimus eluting stent; BVS: bioresorbable vascular scaffold; CAD: coronary artery disease; EES: everolimus eluting stent; LLL: late lumen loss; na: data not available; pts: patients;  
SD: standard deviation; TLR: target lesion revascularisation; TVR: target vessel revascularisation; yrs: years 
                                                                                                                                                                                                                                                                                   
17 Defined as development of new pathological Q-wave or creatine kinase rise of two or more times of upper limit of normal accompanied by creatine kinase-MB rise 
18 Post-hoc analysis 
19 Percentage depending on the cardiac biomarker applied for MI 
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Table A1-2: Bioresorbable scaffolds: results from non-randomized controlled and single-arm trials/1 
Trial, author, year,  
reference number 
ABSORB cohort B 
(B1+B2); Ormiston 
2012 [22], Serruys 2010, 
2011, 2014 [23-25] 
CTO-ABSORB 
Vaquerizo (2014) 
[26] 
ASSURE registry; 
Wöhrle 2014 [27] 
B-SEARCH;  
Simsek 2014 [28]20 
BVS STEMI first 
study; Diletti 2014 
[29] 
Wiebe  
2014 [30] 
POLAR-ACS; 
Dudek 2014 [31] 
Country Europe, New Zealand, 
USA, Australia 
Spain Germany The Netherlands The Netherlands Germany Poland 
Sponsor Abbott Vascular Abbott Vascular Abbott Vascular Abbott Vascular Abbott Vascular na21 na 
Intervention/Product Everolimus-eluting 
bioresorbable scaffold 
(ABSORB ®) 
Everolimus-eluting 
bioresorbable 
scaffold  
(ABSORB ®) 
Everolimus-eluting 
bioresorbable 
scaffold  
(ABSORB ®) 
Everolimus-eluting 
bioresorbable scaffold 
(ABSORB ®) 
Everolimus-eluting 
bioresorbable 
scaffold  
(ABSORB ®) 
Everolimus-eluting 
bioresorbable 
scaffold  
(ABSORB ®) 
Everolimus-eluting 
bioresorbable 
scaffold  
(ABSORB ®) 
Comparator - - - - - - - 
Study design Prospective single-arm 
study 
Prospective  
single-arm study 
Prospective  
single-arm study 
Prospective single-arm 
study 
Prospective 
single-arm study 
Prospective 
single-arm study 
Prospective 
single-arm study 
Number of pts 101 33 183 88 49 25 100 
Sex (n, % male) 73 (72) 28 (80) 146 (80) 64 (73) 38 (78) 19 (76) STEMI: 13 (81); 
NSTEMI: 23 (61); 
UA: 37 (80) 
Mean age of patients: 
yrs  
62 (±9) 61 (±10) 63 (±9) 61 (±9) 60 (±11) 60 (±11) STEMI: 54 (±9); 
NSTEMI: 68 (±11); 
UA: 61 (±10) 
Inclusion criteria Max. 2 de novo native 
coronary artery lesions 
(max. ø 3 mm,  
length ≤14mm,  
% diameter stenosis 
≥50 and <100% 
At least 1 chronic 
total occlusion 
(CTO),  
ø 2.5 to 3.5 mm, 
18 to 75 years, 
ischaemic heart 
disease, 1 or more 
de novo native 
coronary artery 
lesions;  
ø: ≥2 and ≤3.8 mm 
ABSORB cohort A+B: 
Max. 2 de novo native 
coronary artery lesions 
(max. ø 3 mm,  
length ≤14mm,  
% diameter stenosis 
≥50 and <100%) 
ABSORB Extend:  
max. 2 de novo native 
coronary artery lesions, 
length: ≤28mm 
Patients with 
STEMI, ≥18 years, 
vessels ≥2 and 
≤3.8 mm 
Patients with 
STEMI 
Patients with 
acute coronary 
syndrome 
(STEMI, NSTEMI, 
UA) 
Follow-up (months) 36 6 12 1 1 6 12 
Loss to follow-up,  
n (%) 
1 (2) 0 3 (2) 0 0 1 (4) 2 (2) 
                                                             
20 Includes patients from ABSORB cohort A, ABSORB cohort B and ABSORB EXTEND that were treated in the Netherlands 
21 Author(s) received speaker honoraria from Abbott Vascular 
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Trial, author, year,  
reference number 
ABSORB cohort B 
(B1+B2); Ormiston 
2012 [22], Serruys 2010, 
2011, 2014 [23-25] 
CTO-ABSORB 
Vaquerizo (2014) 
[26] 
ASSURE registry; 
Wöhrle 2014 [27] 
B-SEARCH;  
Simsek 2014 [28]20 
BVS STEMI first 
study; Diletti 2014 
[29] 
Wiebe  
2014 [30] 
POLAR-ACS; 
Dudek 2014 [31] 
Anti-platelet therapy  Clopidogrel 75 mg for  
6 months + aspirin 
lifelong according to 
ESC guideline 
na Aspirin 100 mg + 
clopidogrel 75 mg 
for 6 months 
continued with 
aspirin 100 mg 
na Type: na; 
duration:  
12 months 
na According to ESC 
guideline for  
12 months 
Outcomes 
Safety 
Overall 
complications; n (%) 
na 1 (3) 11 (6) 0 0 4 (16) 3 (3) 
Scaffold/stent 
thrombosis; n (%) 
0 0 0 0 0 1 (4)22 1 (1)23 
Periprocedural 
mortality, n (%)  
0 0 0 0 0 unclear24 0 
Periprocedural 
myocardial 
infarction; n (%) 
na 0 0 0 0 0 2 (2) 
Bleeding from anti-
platelet therapy; n (%) 
na na 8 (4) na na na na 
Procedure-related 
contrast-induced 
nephropathy; n (%) 
na 0 na na na na na 
Vascular access site 
complication; n (%) 
na 1 (3) na na na na na 
Mortality from 
bleeding or stroke 
0 0 1 0 0 na 0 
Other serious adverse 
events 
na na 3 (2)25 na na 3 (12)26 na 
CTO: chronic total occlusion; ESC: European Society of Cardiology; na: data not available; NSTEMI: non-ST-segment elevation myocardial infarction; pts: patients; STEMI:  
ST-elevation myocardial infarction; UA: unstable angina; yrs: years 
 
                                                             
22 Two days after implantation 
23 Definite stent thrombosis which caused MI 
24 Inconsistency between cases of death in table (1) and text in paper (0) 
25 Stroke/transient ischaemic attack 
26 One stroke, one pneumonia, one ventricular tachycardia 
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Table A1-3: Bioresorbable scaffolds: results from non-randomized controlled and single-arm trials/2 
Trial, author, year,  
reference number Jaguszewski 2014 [32] Prague 19; Kocka 2014 [33] Gori 2013 [34] DESolve; Verheye 2014 [35] 
Country Switzerland Czech Republic Germany Belgium, New Zealand, 
Sponsor Abbott Vascular Public27 Public27 Elixir Medical 
Intervention/Product Everolimus-eluting bioresorbable 
scaffold (ABSORB®) 
Everolimus-eluting bioresorbable 
scaffold (ABSORB®) 
Everolimus-eluting bioresorbable 
scaffold (ABSORB ®) 
DESolve myolimus eluting 
bioresorbable coronary scaffold 
system 
Comparator - a) Drug eluting or bare metal stent 
b) no stent 
XIENCE PRIME™ metal everolimus 
eluting stent 
- 
Study design Prospective single-arm study Non-randomised controlled study Non-randomised controlled study Prospective single-arm study 
Number of pts 106 142 (40 vs. 57 vs. 45) 253 (150 vs. 103) 16 
Sex (n, % male) 81 (76) 31 (78) vs. 43 (75) vs. 25 (56) 110 (73) vs. 72 (70) 10 (63) 
Age of patients: yrs  61 (±11) 59 (11)28 vs. 64 (13) vs. 69 (13) 62 (±13) vs. 62 (±11) 69 (±8) 
Inclusion criteria Patients with CAD or ACS, at least 1 
coronary artery lesion 
Patients with STEMI<24 h from 
symptom onset 
Patients with ACS (UA, STEMI, 
NSTEMI) with de novo lesions in 
native coronary artery 
Patients with myocardial ischaemia, 
1 de novo native coronary artery 
lesion, ø≤3mm, length ≤10mm 
Follow-up (months) ~5 6 629 12 
Loss to follow-up, n (%) 8 (8) 23 (58 ) vs. 32 (56) vs. na30 na 1 (6) 
Anti-platelet therapy 
therapy 
Aspirin 100 mg + clopidogrel 75 mg, 
prasugrel 10 mg or ticagrelor  
2 x 90 mg for 12 months 
Preferred but not mandated: 
Aspirin + prasugrel, 6 to 12 months 
Aspirin 100 mg + clopidogrel, 
prasugrel or ticagrelor for  
12 months 
Aspirin ≥75 mg + clopidogrel  
75 mg for min. 12 months 
Outcomes 
Efficacy 
Overall complications; 
n (%) 
na 2 (5) vs. 4 (7) vs. na na 2 (13) 
Scaffold/stent thrombosis; 
n (%) 
231 1 (3) vs. 0 vs. nr. 1 month definite 
3 (2) vs. 3 (3); p=1 
1 month probable 
1 (0.7) vs. 1 (1); p=1 
0 
                                                             
27 Author(s) received speaker honoraria from Abbott Vascular 
28 Standard deviation 
29 Only one-month data extracted because six-month follow up was not completed at time of publication 
30 Drop-outs inconsistent between figure and text in publication 
31 One acute, one sub-acute 
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53 
Trial, author, year,  
reference number Jaguszewski 2014 [32] Prague 19; Kocka 2014 [33] Gori 2013 [34] DESolve; Verheye 2014 [35] 
Periprocedural mortality,  
n (%)  
na 0 vs. 1 (2) vs. na 1 (1) vs. 1 (1) 
p=1 
0 
Periprocedural myocardial 
infarction; n (%) 
na 0 vs. 0 vs. na 3 (2) vs. 1 (1) 
p=0.63 
1 (6) 
Bleeding from anti-platelet 
therapy; n (%) 
na na na na 
Procedure-related 
contrast-induced 
nephropathy; n (%) 
na na na na 
Vascular access site 
complication; n (%) 
na na na na 
Mortality from 
bleeding/stroke 
na 0 vs. 0 vs. na 0 vs. 0 0 
Other serious adverse 
events 
2 (2)32 na 1 month 
1 (1) vs. 2 (2)33 
1(6)34 
ACS: acute coronary syndrome; CAD: coronary artery disease; na: data not available; nr: not relevant 
 
  
                                                             
32 All-cause death, one of cardiovascular cause 
33 Within 1 month: Bioresorbable scaffold group: 1 sudden death; DES group: 2 sudden deaths (one due to in-stent thrombosis) 
34 Death following non-target vessel coronary artery bypass grafting 
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Risk of bias tables 
Internal validity of the included studies was judged by two independent researchers. In case of disagreement a third researcher was involved to solve the differences. 
A more detailed description of the criteria used to assess the internal validity of the individual study designs can be found in the Internal Manual of the LBI-HTA 
and in the Guidelines of EUnetHTA [36]. 
Table A2-1: Risk of bias – study level (randomised studies)  
Trial 
Adequate generation  
of randomisation sequence 
Adequate allocation 
concealment 
Blinding Selective outcome 
reporting unlikely 
No other aspects which 
increase the risk of bias 
Risk of bias – 
study level Patient Treating Physician 
ABSORB II [16] Yes Yes (Yes)35 No Yes No36 High 
EVERBIO II [21] Yes Yes No37 No Yes Yes Low 
 
Table A2-2: Risk of bias – study level (non-randomised controlled studies, see [37]) 
Study  
reference/ID 
How was the treatment 
group determined for 
each patient? 
Were treatment groups 
comparable at baseline? 
What steps were taken 
to minimise bias? 
Were all relevant 
outcomes reported? 
Was intention-to-treat 
appropriately 
implemented? 
Any other problems that 
could put the study at a 
high risk of bias 
Prague 19;  
Kocka 2014 [33] 
Allocation to groups 
was based on 
eligibility of patients 
No (better prognosis 
for control group 
patients) 
None Partly Unclear Selection bias because 
of non-randomised 
design 
Gori 2013 [34] Choice was based on 
availability of 
scaffolds 
No None Partly Unclear Selection bias because 
auf non-randomised 
design 
 
                                                             
35 37 patients in intervention group and five in control group were potentially unblinded through discharge letters to referring physicians,  
some outcomes (e.g., angina) likely to be influenced by broken blinding 
36 Cumulative angina rate was post-hoc analysis 
37 No blinding, however, the outcomes defined in the study are not likely to be influenced by lack of blinding 
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Table A2-3: Risk of bias case series (see [38]) 
 
ABSORB 
cohort B 
[22-25] 
CTO-
ABSORB 
[26] 
ASSURE 
registry[27] 
B-SEARCH 
[28] 
BVS STEMI 
first study 
[29] 
Wiebe 
2014 [30] 
POLAR-ACS; 
Dudek 2014 
[31] 
Jaguszewski 
2014[32] 
DESolve; 
Verheye 
2014 [35] 
Study objective 
Is the hypothesis/aim/objective of the study stated 
clearly in the abstract, introduction, or methods section? 
yes yes yes yes yes yes yes yes yes 
Study population 
Are the characteristics of the participants included in 
the study described? 
yes yes yes yes yes yes yes yes yes 
Were the cases collected in more than one centre? yes no yes yes no na yes yes yes 
Are the eligibility criteria (inclusion and exclusion 
criteria) for entry into the study explicit and 
appropriate? 
yes yes yes yes yes no38 yes yes yes 
Were participants recruited consecutively? yes yes yes no44 no39 no39 yes no40 na41 
Did participants enter the study at similar point in the 
disease? 
no42 no43 no43 no44 no43 no43 no45 no43 no43 
Intervention and co-intervention 
Was the intervention clearly described in the study? yes yes yes yes yes yes yes yes yes 
Were additional interventions (co-interventions) 
clearly reported in the study? 
yes yes yes yes yes yes yes yes yes 
Are the outcome measures clearly defined in the 
introduction or methods section? 
yes yes yes yes yes yes yes yes yes 
Were relevant outcomes appropriately measured with 
objective and/or subjective methods? 
yes yes yes yes yes yes yes yes yes 
Were outcomes measured before and after 
intervention? 
na46 na46 na46 na46 na46 na46 na46 na46 na46 
                                                             
38 Exclusion criteria not defined 
39 Arbitrary allocation to BVS 
40 Selection of patients at discretion of operator 
41 Unclear whether all consecutive patients were included 
42 In 41 from 101 patients BVS was implanted in vessels with ≤2.5 mm diameter while study protocol defined 3mm vessel diameter 
43 Different history of MI, revascularisation, vessel anatomy  
44 Analysis combines data from different studies 
45 Patients with different types of acute coronary syndrome (NSTEMI, STEMI) 
46 For safety outcomes not applicable 
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ABSORB 
cohort B 
[22-25] 
CTO-
ABSORB 
[26] 
ASSURE 
registry[27] 
B-SEARCH 
[28] 
BVS STEMI 
first study 
[29] 
Wiebe 
2014 [30] 
POLAR-ACS; 
Dudek 2014 
[31] 
Jaguszewski 
2014[32] 
DESolve; 
Verheye 
2014 [35] 
Statistical analysis 
Were the statistical tests used to assess the relevant 
outcomes appropriate? 
yes yes yes yes yes yes yes yes yes 
Results and conclusions 
Was the length of follow-up reported? yes yes yes yes yes yes yes yes yes 
Was the loss to follow-up reported? yes yes yes yes yes yes yes yes yes 
Does the study provide estimates of the random 
variability in the data analysis of relevant outcomes? 
na47 na47 na47 na47 na47 na47 na47 na47 na47 
Are adverse events reported? partly partly partly partly partly partly partly partly partly 
Are the conclusions of the study supported by results? yes yes yes yes yes yes yes yes yes 
Competing interests and sources of support 
Are both competing interests and sources of support 
for the study reported? 
yes yes yes yes yes no48 no yes yes 
Na: data not available 
 
  
                                                             
47 Data reported are absolute counts 
48 Sources of support not reported 
  
A
p
p
en
d
ix 
LB
I-H
T
A
 | 20
15 
57 
Table A2-4: Risk of bias – outcome level  
Outcome 
Trial 
Risk of bias –  
study level 
Blinding –  
outcome assessors 
ITT principle 
adequately realized 
Selective outcome 
reporting unlikely 
No other aspects 
according to risk of bias 
Risk of bias –  
outcome level 
Efficacy 
All-cause mortality 
ABSORB II [16] High Low Low Low Low Low 
EVERBIO II [21] Low Low High Low Low Low 
Cardiac mortality 
ABSORB II [16] High Low Low Low Low Low 
EVERBIO II [21] Low Low High Low Low Low 
MI 
ABSORB II [16] High Low Low Low Low Low 
EVERBIO II [21] Low Low High Low Low Low 
Composite endpoint (death, MI, revascularisation) 
ABSORB II [16] High Low Low Low Low Low 
EVERBIO II [21] Low Low High Low Low Low 
Angina 
ABSORB II [16] High High Low Low Low High 
Health related quality of life 
ABSORB II [16] High High Low Low Low High 
Revascularisation 
ABSORB II [16] High High Low Low Low High 
EVERBIO II [21] Low Low High Low Low Low 
Safety 
Overall complications 
CTO-ABSORB [26] High High High Low High High 
ASSURE registry [27] High High High Low High High 
B-SEARCH [28] High High Low Low High High 
BVS STEMI first [29] High High Low Low High High 
Wiebe [30] High High Low Low High High 
POLAR-ACS [31] High High High Low High High 
Prague 19 [33] High High High Low High High 
DESolve [35] High High High Low High High 
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Outcome 
Trial 
Risk of bias –  
study level 
Blinding –  
outcome assessors 
ITT principle 
adequately realized 
Selective outcome 
reporting unlikely 
No other aspects 
according to risk of bias 
Risk of bias –  
outcome level 
Scaffold/Stent-thrombosis 
ABSORB II [16] High Low Low Low Low Low 
EVERBIO II [21] Low Low High Low Low Low 
ABSORB cohort B [22-25] High High Low Low High High 
CTO-ABSORB [26] High High High Low High High 
ASSURE registry [27] High High High Low High High 
B-SEARCH [28] High High Low Low High High 
BVS STEMI first [29] High High Low Low High High 
Wiebe [30] High High Low Low High High 
POLAR-ACS [31] High High High Low High High 
Jaguszewski [32] High High High Low High High 
Prague 19 [33] High High High Low High High 
Gori [34] High High High Low High High 
DESolve [35] High High High Low High High 
Procedure-related mortality 
ABSORB II [16] High Low Low Low Low Low 
ABSORB cohort B [22-25] High Low Low Low High High 
CTO-ABSORB [26] High Low High Low High High 
ASSURE registry [27] High Low High Low High High 
B-SEARCH [28] High Low Low Low High High 
BVS STEMI first [29] High Low Low Low High High 
Wiebe [30] High Low Low Low High High 
POLAR-ACS [31] High Low High Low High High 
Prague 19 [33] High Low High Low High High 
Gori [34] High Low High Low High High 
DESolve [35] High Low High Low High High 
Periprocedural myocardial infarction 
ABSORB II [16] HIgh Low Low Low Low Low 
CTO-ABSORB [26] High Low High Low High High 
ASSURE registry [27] High Low High Low High High 
B-SEARCH [28] High Low Low Low High High 
BVS STEMI first [29] High Low Low Low High High 
Wiebe [30] High Low Low Low High High 
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Outcome 
Trial 
Risk of bias –  
study level 
Blinding –  
outcome assessors 
ITT principle 
adequately realized 
Selective outcome 
reporting unlikely 
No other aspects 
according to risk of bias 
Risk of bias –  
outcome level 
POLAR-ACS [31] High Low High Low High High 
Prague 19 [33] High Low High Low High High 
Gori [34] High Low High Low High High 
DESolve [35] High Low High Low High High 
Bleeding from anti-platelet therapy  
ASSURE registry [27] High High High Low High High 
Procedure-related contrast-induced nephropathy 
CTO-ABSORB [26] High High High Low High High 
Vascular access site complication 
CTO-ABSORB [26] High High High Low High High 
Mortality from bleeding/stroke 
ABSORB cohort B [22-25] High Low Low Low High High 
CTO-ABSORB [26] High Low High Low High High 
ASSURE registry [27] High Low High Low High High 
B-SEARCH [28] High Low Low Low High High 
BVS STEMI first [29] High Low Low Low High High 
POLAR-ACS [31] High Low High Low High High 
Prague 19 [33] High Low High Low High High 
Gori [34] High Low High Low High High 
DESolve [35] High Low High Low High High 
Other serious adverse events 
ASSURE registry [27] High High High Low High High 
Wiebe [30] High High Low Low High High 
Jaguszewski [32] High High High Low High High 
Gori [34] High High High Low High High 
DESolve [35] High High High Low High High 
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Applicability table 
Table A3-1: Summary table characterising the applicability of a body of studies 
Domain Description of applicability of evidence 
Population The patients in most of the studies were predominantly males with a mean age of around  
60 years and with relatively simple lesions in contrast to patients with more complex lesions 
and wider age ranges frequently encountered in daily practice. The generalisabilty is 
therefore limited. 
Furthermore, the study population is predominantly male, hence, generalisability to females 
is limited. 
Most of the patients had stable CAD and very few studies, yet with high risk of bias, have 
included patients with acute coronary artery syndrome. The results are, therefore, only valid 
for a population with stable CAD. 
Intervention The implantation procedure does not differ from routine use. However, patients in the 
studies underwent multiple imaging procedures. Compared to routine use, this could have 
resulted in positive or negative consequences (false-positive, false-negative results etc.) 
Comparators In the only RCT available, the BVS was compared to a DES. In routine practice, other stent 
types and further revascularisation strategies (CABG) will be taken into consideration. From 
the current evidence we do not know whether the BVS is superior to those approaches in 
terms of benefits and harms. 
Outcomes The primary outcome in the current key study [16] is a surrogate endpoint which does not 
reflect the most important clinical benefits and harms. The secondary outcomes in this study 
and the outcomes in the observational studies are patient-relevant, however, the follow-up 
has mostly been 6 to 12 months only and thus, the superiority of the BVS in term so long-
term safety issues (especially late and very late scaffold thrombosis, fatal events) cannot be 
judged yet. 
Setting The setting in the studies has not been described precisely but most of the procedures seem 
to have been undertaken in highly specialised university units. The transferability to a low-
volume cardiac catheterisation lab with less experienced cardiologists may be limited. 
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Ongoing studies 
Table A4-1: Ongoing studies 
Study Identifier Time Study type N Intervention Comparator Patient population Primary endpoints 
ABSORB® 
NCT01986803 
(TROFI II Study) 
Sponsor: ECRI-bv 
2015–2017 RCT  
(single-blind) 
190 Abbott vascular ABSORB 
Everolimus Eluting 
Bioresorbable Vascular 
Scaffold System 
XIENCE Xpedition 
stent 
Acute ST-Elevation 
myocardial infarction 
Healing Score 
NCT01425281 
(ABSORB II) 
Sponsor: Abbott Vascular 
2011–2018 RCT  
(single-blind) 
501 Abbott vascular ABSORB 
Everolimus Eluting 
Bioresorbable Vascular 
Scaffold System 
Abbott Vascular 
XIENCE Everolimus 
Eluting Coronary 
Stent System 
Patients with CAD caused by 
up to two de novo native 
coronary artery lesions in 
separate vessels 
Vasomotion, MLD 
NCT01751906  
(ABSORB III) 
Sponsor: Abbott Vascular 
2012–2019 RCT  
(single-blind 
2250 Abbott vascular ABSORB 
Everolimus Eluting 
Bioresorbable Vascular 
Scaffold System 
Abbott Vascular 
XIENCE Everolimus 
Eluting Coronary 
Stent System 
Subjects with de novo native 
coronary artery lesions 
Target lesion failure 
(TLF) at 1 year  
(non-inferiority) 
NCT01844284 
(ABSORB Japan) 
Sponsor: Abbott Vascular 
2013–2019 RCT  
(single-blind) 
400 Abbott vascular ABSORB 
Everolimus Eluting 
Bioresorbable Vascular 
Scaffold System 
Abbott Vascular 
XIENCE 
PRIME®/XIENCE 
Xpedition 
Subjects with ischemic heart 
disease caused by de novo 
native coronary artery 
lesions 
Target Lesion Failure 
(TLF), non-inferiority 
NCT01858077 
(Amsterdam Investigator-initiateD 
Absorb Strategy All-comers 
Trial/AIDA) 
Sponsor: Academisch Medisch 
Centrum – Universiteit van 
Amsterdam (AMC-UvA)  
2013 -2020 RCT  
(single-blind) 
2690 Abbott vascular ABSORB 
Everolimus Eluting 
Bioresorbable Vascular 
Scaffold System 
Abbott Vascular 
XIENCE 
PRIME®/XIENCE 
Xpedition 
Coronary lesions in 
consecutive all-comers 
Target vessel failure 
(TVF) 
NCT02173379 
(ABSORB IV) 
Sponsor: Abbott Vascular 
2014–2021 RCT  
(single-blind) 
3000 Abbott vascular ABSORB 
Everolimus Eluting 
Bioresorbable Vascular 
Scaffold System 
Abbott Vascular 
XIENCE Everolimus 
Eluting Coronary 
Stent System 
Subjects with de novo native 
coronary artery lesions 
Percentage of patients 
who experienced angina 
within 1 year,  
(non-inferiority) 
NCT02151929 
Sponsor: San Giuseppe Moscati 
Hospital 
2013–2014 RCT 
(unblinded) 
100 Abbott vascular ABSORB 
Everolimus Eluting 
Bioresorbable Vascular 
Scaffold System 
Abbott Vascular 
XIENCE PRIME® 
Patients with ST elevation 
myocardial infarction 
Procedural and Clinical 
success 
NCT01942070 
(ISAR- ABSORB MI) 
Sponsor: Deutsches 
Herzzentrum Muenchen 
2013–2015 RCT 
(unblinded) 
260 Abbott vascular ABSORB 
Everolimus Eluting 
Bioresorbable Vascular 
Scaffold System 
Durable polymer 
everolimus-eluting 
metallic stent 
(EES) 
Patients undergoing PCI in 
the setting of acute MI 
Percentage Diameter 
Stenosis 
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Study Identifier Time Study type N Intervention Comparator Patient population Primary endpoints 
NCT02171065  
(PROSPECT ABSORB) 
Sponsor: Uppsala University 
2014–2018 RCT 
(unblinded) 
900 ABSORB BVS + Guideline 
Directed Medical 
Therapy 
Sham + ABSORB 
BVS 
Patients with acute coronary 
syndrome 
Non-culprit major 
adverse cardiac event 
(NC-MACE) 
NCT01923740 
(ABSORB CHINA RCT) 
Sponsor: Abbott Vascular 
2013–2019 RCT 
(unblinded) 
480 Abbott vascular ABSORB 
Everolimus Eluting 
Bioresorbable Vascular 
Scaffold System 
Abbott Vascular 
XIENCE Everolimus 
Eluting Coronary 
Stent System 
Patients with ischemic heart 
disease caused by up to two de 
novo native coronary artery 
lesions in separate vessels 
In-segment late loss 
NCT02067091 
(BVS in STEMI) 
Sponsor: Haukeland University 
Hospital 
2014–2020 RCT 
(unblinded) 
120 Abbott vascular ABSORB 
Everolimus Eluting 
Bioresorbable Vascular 
Scaffold System 
Xience pro Patients presenting with ST 
elevation myocardial 
infarction for primary PCI 
(percutaneous coronary 
intervention) 
Coronary stent healing 
index 
NCT02001025 
Sponsor: Medical University 
Vienna 
2013–na Non-
randomised 
controlled trial 
60 Abbott vascular ABSORB 
Everolimus Eluting 
Bioresorbable Vascular 
Scaffold System 
Xience stent Patients with CAD and 
multiple lesions to be treated 
adverse post-stenting 
results 
NCT01759290 
(ABSORB First) 
Sponsor: Abbott Vascular 
2013–2015 Single-arm 
registry 
1801 Abbott vascular ABSORB 
Everolimus Eluting 
Bioresorbable Vascular 
Scaffold System 
- Patients with de novo lesions 
in previously untreated 
vessels 
Cardiac death/target 
vessel-MI/ischaemia 
driven-target lesion 
revascularisation 
NCT02004730 
(IT DISAPPEARS) 
Sponsor: Istituto Clinico 
Sant'Ambrogio 
2013–2015 Single-arm 
registry 
1000 Abbott vascular ABSORB 
Everolimus Eluting 
Bioresorbable Vascular 
Scaffold System 
- Patients with diffuse or 
multivessel coronary artery 
disease 
Major adverse cardiac 
events 
NCT02071342 
(ABSORB-ACS) 
Sponsor: Umberto I Hospital, 
Frosinone Italy 
2013–2015 Single-arm 
registry (Italian 
Registry) 
300 Abbott vascular ABSORB 
Everolimus Eluting 
Bioresorbable Vascular 
Scaffold System 
- Patients with myocardial 
infarction 
Major adverse cardiac 
events 
NCT01583608  
(ASSURE) 
Sponsor: Medical Care Center 
Prof. Mathey, Prof. Schofer, Ltd. 
2012–2016 Single-arm 
registry 
180 Everolimus-eluting 
Bioresorbable Vascular 
Scaffold 
- Patients with de novo native 
coronary artery lesions in  
all-day clinical practice 
No primary endpoint 
defined 
NCT01915420 
(ASSURE-ROT registry) 
Sponsor: Medical Care Center 
Prof. Mathey, Prof. Schofer, Ltd. 
2013–2017 Single-arm 
registry 
42 Everolimus-eluting 
Bioresorbable Vascular 
Scaffold 
- Following rotational 
atherectomy in patients with 
complex de novo native 
coronary artery lesions in  
all-day clinical practice 
Major adverse cardiac 
event 
NCT01977534 
(ABSORB UK) 
Sponsor: Abbott Vascular 
2014–2018 Single-arm 
registry 
1000 Abbott vascular ABSORB 
Everolimus Eluting 
Bioresorbable Vascular 
Scaffold System 
- Patients with de novo lesions Acute success: device 
success (lesion based 
analysis) 
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Study Identifier Time Study type N Intervention Comparator Patient population Primary endpoints 
NCT02066623 
(GABI-R) 
Sponsor: IHF GmbH-Institut für 
Herzinfarktforschung 
2013–2020 Single-arm 
German-Austrian 
registry 
5000 Abbott vascular ABSORB 
Everolimus Eluting 
Bioresorbable Vascular 
Scaffold System 
- Patients with coronary 
artery stenosis 
Number of serious 
adverse cardiac events 
NCT02298413 
(Italian Absorb Registry/BVS RAI) 
Sponsor: Ospedale Santa  
Croce-Carle Cuneo 
2013–2021 Single-arm 
registry (Italian 
Registry) 
2000 Abbott vascular ABSORB 
Everolimus Eluting 
Bioresorbable Vascular 
Scaffold System 
- All-comers study, and 
includes all consecutive 
patients who have been 
treated with 1 or more BVS 
Scaffold thrombosis, 
target lesion 
revascularisation 
NCT02238054 
(FRANCE ABSORB) 
Sponsor: French Cardiology 
Society 
2014–2022 Single-arm 
registry 
2000 Abbott vascular ABSORB 
Everolimus Eluting 
Bioresorbable Vascular 
Scaffold System 
- All patients with a coronary 
angioplasty procedure and 
the implantation of at least 
one ABSORB BVS 
Major adverse cardiac 
events 
DESolve® 
NCT02086006 
(DESolve I trial) 
Sponsor: Elixir Medical 
Corporation 
2011–2016 Single-arm 16 DESolve Myolimus 
Eluting Bioresorbable 
Coronary Stent System 
- Patients with de novo 
coronary artery lesions 
Major adverse cardiac 
events, target vessel 
failure, target vessel 
revascularisation, acute 
success, stent thrombosis 
NCT02086045 
DESolve Nx Trial 
Sponsor: Elixir Medical 
Corporation 
2011- 2017 Single-arm 126 DESolve® Novolimus 
Eluting Bioresorbable 
Coronary Scaffold 
System 
- Patients with a single de 
novo native coronary artery 
lesion 
Clinically-indicated 
major adverse cardiac 
events 
NCT02013349 
(DESolve post approval study) 
Sponsor: Elixir Medical 
Corporation 
2014–2020 Single-arm 200 DESolve Novolimus 
Eluting Bioresorbable 
Coronary Scaffold 
System 
- Patients with de novo 
coronary artery lesions 
Major adverse cardiac 
events 
NeoVas 
NCT02305485 
Sponsor: Lepu Medical 
Technology (Beijing) Co.,Ltd 
2014–2020 RCT  
(single-blind) 
560 NeoVas sirolimus-
eluting bioresorbable 
coronary scaffold 
XIENCE PRIME 
Everolimus Eluting 
Coronary Stent 
System 
Patients with de novo 
coronary artery lesion 
In-segment late lumen 
loss 
NCT02195414 
(NeoVas Bioresorbable Coronary 
Scaffold first-in-man study) 
Sponsor: Lepu Medical 
Technology (Beijing) Co.,Ltd 
2014–2019 Single-arm 30 NeoVas sirolimus-
eluting bioresorbable 
coronary scaffold 
- Patients with de novo 
coronary lesion 
Target lesion failure 
NCT02305472 
Sponsor: Lepu Medical 
Technology (Beijing) Co.,Ltd 
2014–2020 Single-arm 
registry 
825 NeoVas sirolimus-
eluting bioresorbable 
coronary scaffold 
- Patients with de novo 
coronary artery lesion 
Target lesion failure 
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Study Identifier Time Study type N Intervention Comparator Patient population Primary endpoints 
Fortitude 
NCT02255864 
Sponsor: Amaranth Medical 
2015–2020 Single-arm 120 Amaranth Medical 
FORTITUDE 
Bioresorbable Drug-
Eluting Coronary Stent 
- Single, de novo, stenotic 
native coronary artery lesions 
in patients undergoing elective 
percutaneous coronary 
intervention 
In-scaffold late lumen 
loss, incidence of target 
vessel failure 
NCT02189499 
Sponsor: Amaranth Medical Inc. 
2014–2020 Single-arm 50 Amaranth Medical 
FORTITUDE 
Bioresorbable Drug-
Eluting Coronary Stent 
- Single, de novo, stenotic 
native coronary artery lesions 
in patients undergoing elective 
percutaneous coronary 
intervention 
Target vessel failure, in-
scaffold late lumen loss 
ReZolve 
NCT01845311 
RESTORE II 
Sponsor: REVA Medical, Inc. 
2013–2018 Single-arm 125 ReZolve2 Sirolimus-
Eluting Bioresorbable 
Coronary Scaffold 
- na Major adverse cardiac 
events, late lumen loss 
ART18Z 
NCT01761578 
(ARTDIVA) 
Sponsor: Arterial Remodeling 
Technologies 
2012–2013 Single-arm 30 ART18Z Bioresorbable 
Stent 
- Patients with single de novo 
lesion of a native coronary 
artery 
Major adverse cardiac 
events 
Biosolve 
NCT01960504 
(BIOSOLVE II) 
Sponsor: Biotronik AG 
2013–2018 Single-arm 121 2nd Generation Drug 
Eluting Absorbable Metal 
Scaffold (BIOSOLVE-II) 
- Subjects with de novo lesions 
in native coronary arteries 
In segment Late Lumen 
Loss 
Studies with unspecified products 
NCT02316886 
(PREVENT) 
Sponsor: Seung-Jung Park 
2014–2019 RCT(unblinded) 2000 Bioresorbable Vascular 
Scaffold 
Optimal medical 
Treatment 
Patients with functionally 
insignificant coronary stenosis 
with vulnerable plaque 
Cardiovascular death, 
non-fatal MI, unplanned 
hospitalisation 
NCT02334826 
(RELEASE BVS) 
Sponsor: Poznan University of 
Medical Sciences 
2015–2022 RCT 
(unblinded) 
140 Bioresorbable Vascular 
Scaffold 
CABG Patients with advanced 
stable ischemic heart disease 
Extent of ischemia and 
left ventricular ejection 
fraction in cardiovascular 
magnetic resonance 
NCT02256449 
(REPARA study) 
Sponsor: Sección Hemodinamica 
y Cardiologia Intervencionista 
2014–2016 Single-arm 
registry 
1500 Bioresorbable coronary 
device 
- Patients undergoing PCI in 
de novo coronary artery 
lesions 
Major adverse cardiac 
events 
NCT02162056 
(CSI-Ulm-BVS) 
Sponsor: University of Ulm 
2013–2028 na 2000 Bioresorbable Vascular 
Scaffold 
- Patients with CAD Major adverse cardiac 
events 
CAD: coronary artery disease 
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Literature search 
Search strategy for Medline (via Ovid) 
Database: Ovid MEDLINE(R) <1946 to November Week 3 2014>, Ovid MEDLINE(R) In-Process & 
Other Non-Indexed Citations <January 05, 2015>, Ovid MEDLINE(R) Daily Update <November 19, 
2014>, Ovid OLDMEDLINE(R) <1946 to 1965> 
Search Strategy: 
1 *Angina, Stable/(352) 
2 *Angina, Unstable/(5532) 
3 *Angina Pectoris/(19222) 
4 angina*.mp. (64064) 
5 *Myocardial Infarction/(109006) 
6 *Myocardial Ischemia/(24154) 
7 myocard*.mp. (481367) 
8 *Coronary Artery Disease/(33563) 
9 *Acute Coronary Syndrome/(7275) 
10 *Coronary Disease/(95891) 
11 coronary.mp. (416260) 
12 *Heart Diseases/(40846) 
13 heart*.mp. (1047239) 
14 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 (1424379) 
15 bioabsorbable*.mp. (1940) 
16 bio-absorbable*.mp. (75) 
17 biodegradable*.mp. (16737) 
18 bio-degradable*.mp. (47) 
19 exp Biodegradable Plastics/(61) 
20 bioresorbable*.mp. (1439) 
21 bio-resorbable*.mp. (21) 
22 exp Biocompatible Materials/(77195) 
23 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 (91178) 
24 *Percutaneous Coronary Intervention/(3237) 
25 Percutaneous Coronary Intervention*.mp. (21187) 
26 PCI*.mp. (16409) 
27 *Stents/(34487) 
28 *Drug-Eluting Stents/(5387) 
29 stent*.mp. (79974) 
30 *Tissue Scaffolds/(6664) 
31 scaffold*.mp. (56409) 
32 *Absorbable Implants/(3543) 
33 Absorb.ti,ab. (6732) 
34 DEsolve.ti,ab. (1) 
35 DREAMS.ti,ab. (3711) 
36 IDEAL.ti,ab. (75567) 
37 Igaki*.mp. (9) 
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38 Fantom.ti,ab. (55) 
39 ART18Z.mp. (0) 
40 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 (240647) 
41 23 and 40 (16625) 
42 14 and 41 (2315) 
43 exp Clinical Trial/or double-blind method/or (clinical trial* or randomized controlled trial or 
multicenter study).pt. or exp Clinical Trials as Topic/or ((randomi?ed adj7 trial*) or (controlled 
adj3 trial*) or (clinical adj2 trial*) or ((single or doubl* or tripl* or treb*) and (blind* or 
mask*))).ti,ab. (1248704) 
06.01. 5201  
 
Search strategy for Embase 
No Query Results  Results Date 
#1. 'clinical article'/de OR 'clinical study'/de OR 'clinical trial'/de OR 'clinical 
trial (topic)'/de OR 'cohort analysis'/de OR 'comparative study'/de OR 
'controlled clinical trial'/de OR 'controlled study'/de OR 'in vivo study'/de 
OR 'intermethod comparison'/de OR 'major clinical study'/de OR 'meta 
analysis'/de OR 'methodology'/de OR 'multicenter study'/de OR 
'prospective study'/de OR 'randomized controlled trial'/de OR 'randomized 
controlled trial (topic)'/de OR 'systematic review'/de AND ('stable angina 
pectoris'/mj OR 'unstable angina pectoris'/mj OR 'angina pectoris'/mj OR 
'angina pectoris' OR 'heart infarction'/mj OR 'heart muscle ischemia'/mj 
OR myocard* NEAR/1 (infarction* OR ischemia* OR ischaemia*) OR 
'coronary artery disease'/mj OR 'acute coronary syndrome'/mj OR 
'ischemic heart disease'/mj OR coronary NEAR/1 disease* OR 'heart 
disease'/mj OR heart NEAR/1 disease*) AND ('biodegradable implant'/mj 
OR (bioabsorbable OR 'bio-absorbable' OR biodegradable* OR 'bio-
degradable' OR bioresorbable* OR 'bio-resorbable') NEAR/5 (stent* OR 
scaffold* OR implant* OR 'percutaneous coronary intervention' OR 
'percutaneous coronary interventions' OR pci*) OR 'bioresorbable vascular 
stent'/exp OR absorb:dn OR desolve:dn OR dreams:dn OR ideal:dn OR 
igaki:dn OR 'igaki tamai':dn OR fantom:dn OR art18z:dn) AND 'human'/de 
OR ('stable angina pectoris'/mj OR 'unstable angina pectoris'/mj OR 
'angina pectoris'/mj OR 'angina pectoris' OR 'heart infarction'/mj OR 
'heart muscle ischemia'/mj OR myocard* NEAR/1 (infarction* OR 
ischemia* OR ischaemia*) OR 'coronary artery disease'/mj OR 'acute 
coronary syndrome'/mj OR 'ischemic heart disease'/mj OR coronary 
NEAR/1 disease* OR 'heart disease'/mj OR heart NEAR/1 disease* AND 
('biodegradable implant'/mj OR (bioabsorbable OR 'bio-absorbable' OR 
biodegradable* OR 'bio-degradable' OR bioresorbable* OR 'bio-resorbable') 
NEAR/5 (stent* OR scaffold* OR implant* OR 'percutaneous coronary 
intervention' OR 'percutaneous coronary interventions' OR pci*) OR 
'bioresorbable vascular stent'/exp OR absorb:dn OR desolve:dn OR 
dreams:dn OR ideal:dn OR igaki:dn OR 'igaki tamai':dn OR fantom:dn 
OR art18z:dn) AND ([cochrane review]/lim OR [systematic review]/lim 
OR [controlled clinical trial]/lim OR [randomized controlled trial]/lim 
OR [meta analysis]/lim)) 
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Search strategy for CRD 
1 (bioabsorbable*) 
  
   
  
2 (bio-absorbable*) 
3 (biodegradable*) 
4 (bio-degradable*) 
5 MeSH DESCRIPTOR Biodegradable Plastics EXPLODE ALL TREES 
6 (bioresorbable*) 
7 (bio-resorbable*) 
8 MeSH DESCRIPTOR Biocompatible Materials EXPLODE ALL TREES 
9 #1 OR #2 OR #3 OR #5 OR #6 OR #8 
10 MeSH DESCRIPTOR Percutaneous Coronary Intervention EXPLODE ALL TREES 
11 (Percutaneous Coronary Intervention*) 
12 (PCI*) 
13 MeSH DESCRIPTOR Stents EXPLODE ALL TREES 
14 MeSH DESCRIPTOR Drug-Eluting Stents EXPLODE ALL TREES 
15 (stent*) 
16 MeSH DESCRIPTOR Tissue Scaffolds EXPLODE ALL TREES 
17 (scaffold*) 
18 MeSH DESCRIPTOR Absorbable Implants EXPLODE ALL TREES 
19 (Absorb) 
20 (DEsolve) 
21 (DREAMS) 
22 (IDEAL) 
23 (Igaki*) 
24 (Fantom*) 
25 (ART18Z) 
26 #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #21 OR #22 OR #23 
27 #9 AND #26 
51 Hits 
06.01.2015 
 
Search strategy for The Cochrane Library 
Search Name: PCI with bioabsorbable Stents 
Last Saved: 06/01/2015 19:54:52.818 
ID Search 
#1 MeSH descriptor: [Angina, Stable] explode all trees 
#2 MeSH descriptor: [Angina, Unstable] explode all trees 
#3 MeSH descriptor: [Angina Pectoris] explode all trees 
#4 angina* (Word variations have been searched) 
#5 MeSH descriptor: [Myocardial Infarction] explode all trees 
#6 MeSH descriptor: [Myocardial Ischemia] explode all trees 
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#7 myocard* (Word variations have been searched) 
#8 MeSH descriptor: [Coronary Artery Disease] explode all trees 
#9 MeSH descriptor: [Acute Coronary Syndrome] explode all trees 
#10 MeSH descriptor: [Coronary Disease] explode all trees 
#11 coronary (Word variations have been searched) 
#12 MeSH descriptor: [Heart Diseases] explode all trees 
#13 heart* (Word variations have been searched)  
#14 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 
#15 bioabsorbable* (Word variations have been searched) 
#16 bio-absorbable* (Word variations have been searched) 
#17 biodegradable* (Word variations have been searched) 
#18 bio-degradable* (Word variations have been searched) 
#19 MeSH descriptor: [Biodegradable Plastics] explode all trees 
#20 bioresorbable* (Word variations have been searched) 
#21 bio-resorbable* (Word variations have been searched) 
#22 MeSH descriptor: [Biocompatible Materials] explode all trees 
#23 #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 
#24 MeSH descriptor: [Percutaneous Coronary Intervention] explode all trees 
#25 Percutaneous Coronary Intervention* (Word variations have been searched) 
#26 PCI* (Word variations have been searched) 
#27 MeSH descriptor: [Stents] explode all trees 
#28 MeSH descriptor: [Drug-Eluting Stents] explode all trees 
#29 stent* (Word variations have been searched) 
#30 MeSH descriptor: [Tissue Scaffolds] explode all trees 
#31 scaffold* (Word variations have been searched) 
#32 MeSH descriptor: [Absorbable Implants] explode all trees 
#33 Absorb (Word variations have been searched) 
#34 DEsolve (Word variations have been searched) 
#35 DREAMS (Word variations have been searched) 
#36 IDEAL (Word variations have been searched) 
#37 Igaki* (Word variations have been searched) 
#38 Fantom* (Word variations have been searched) 
#39 ART18Z (Word variations have been searched) 
#40 #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33 or #35 or #36 or #37 or #38 
#41 #23 and #40 
#42 #14 and #41 
273 Hits 
 
